Post-viral disorder
MONDO:0021674A post-infectious disorder that follows viral infection but is distinct from the viral infection itself and its usual manifestations.
Also known as: sequela of viral disease
1635 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
Showing the 400 most recently updated of 668 trials in this tab.
-
Engineered immune cells take aim at Hard-to-Treat leukemia
⭐️ CURE ⭐️ Recruiting nowThis early-stage trial is testing an investigational therapy called B019, which uses a patient's own immune cells engineered to recognize and attack leukemia cells. The study focuses on people with B-cell acute lymphoblastic leukemia that has returned or not responded to standard…
Phase: PHASE1 • Sponsor: Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd. • Aim: ⭐️ CURE ⭐️
Last updated Aug 18, 2026 04:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat lymphomas
⭐️ CURE ⭐️ Recruiting nowThis trial is testing an experimental therapy called CD22 CAR T cells in adults with certain types of B cell lymphomas that have come back or not responded to previous treatments. The therapy involves collecting a patient's own immune cells, modifying them to recognize and attack…
Phase: PHASE1 • Sponsor: Stanford University • Aim: ⭐️ CURE ⭐️
Last updated Aug 14, 2026 00:00 UTC
-
Can targeted drugs blinatumomab and venetoclax improve outcomes for childhood leukemia?
⭐️ CURE ⭐️ Recruiting nowThis large trial is testing whether adding the targeted drugs blinatumomab or venetoclax to standard chemotherapy can improve survival and reduce side effects in children with intermediate- or high-risk B-cell acute lymphoblastic leukemia (ALL). The study compares different sched…
Phase: PHASE2, PHASE3 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: ⭐️ CURE ⭐️
Last updated Jul 25, 2026 00:00 UTC
-
Robotic surgery may spare throat cancer patients from chemo and radiation
⭐️ CURE ⭐️ Recruiting nowThis phase 2 trial is testing whether robotic surgery alone can control HPV-related throat cancer, potentially sparing patients the long-term side effects of chemotherapy and radiation. The study enrolls people with HPV-positive oropharyngeal cancer whose tumors are removable and…
Phase: PHASE2 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: ⭐️ CURE ⭐️
Last updated Jul 24, 2026 00:00 UTC
-
Can shingrix shield HIV patients from shingles?
⭐️ VACCINE ⭐️ Recruiting nowThis study tests the Shingrix vaccine in people with HIV and healthy volunteers to see how well it boosts immunity against shingles. Participants receive two shots two months apart and are followed for a year. The goal is to understand if the vaccine works safely in those with di…
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 15, 2026 00:00 UTC
-
Could an extra shingles shot protect transplant patients?
⭐️ VACCINE ⭐️ Recruiting nowThis study looks at how well the shingles vaccine (Shingrix) works in adults with kidney failure who are waiting for a kidney transplant. Researchers want to see if giving an extra dose after the transplant boosts the immune response. About 132 participants will be followed for u…
Phase: PHASE3 • Sponsor: University of Colorado, Denver • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:05 UTC
-
Can the shingles vaccine protect transplant patients? new study aims to find out
⭐️ VACCINE ⭐️ Recruiting nowThis study tests the shingles vaccine (SHINGRIX) in 160 people: transplant recipients on different immunosuppressant drugs and their healthy housemates. Researchers will measure immune responses at five time points over a year to see if the vaccine works well in these groups. The…
Phase: NA • Sponsor: Central Adelaide Local Health Network Incorporated • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:05 UTC
-
New shingles vaccine trial aims to protect vulnerable kids
⭐️ VACCINE ⭐️ Recruiting nowThis study is testing a new shingles vaccine (PED-HZ/su) in children aged 1 to 17 who have had a kidney transplant and have weakened immune systems. The vaccine is given as two shots in the arm. Researchers are checking how safe it is, what side effects occur, and how well it boo…
Phase: PHASE1, PHASE2 • Sponsor: GlaxoSmithKline • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:08 UTC
-
MRNA vaccine aims to prevent shingles in older adults
⭐️ VACCINE ⭐️ Recruiting nowThis study is testing a new mRNA vaccine to prevent shingles (herpes zoster) in adults aged 40 and older. The vaccine uses mRNA technology, similar to some COVID-19 vaccines, and is freeze-dried for easier storage. Researchers will compare different doses against existing vaccine…
Phase: PHASE1, PHASE2 • Sponsor: Sinovac Biotech Co., Ltd • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:04 UTC
-
Can a shingles shot protect transplant patients? timing may be key.
⭐️ VACCINE ⭐️ Recruiting nowThis study looks at how well the shingles vaccine Shingrix works in people who have had a stem cell transplant. About 55 adults who received the vaccine at least a year after their transplant will have their immune responses measured. Researchers want to see if the timing of the …
Phase: PHASE2 • Sponsor: University of Colorado, Denver • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:02 UTC
-
New 11-Valent HPV vaccine aims to block more Cancer-Causing viruses
⭐️ VACCINE ⭐️ Recruiting nowThis Phase 3 trial is testing an 11-valent HPV vaccine in 13,500 Chinese women aged 18-45. The vaccine targets 11 types of HPV linked to cervical cancer and genital warts. Participants receive three shots over six months and are monitored for several years to see if the vaccine p…
Phase: PHASE3 • Sponsor: National Vaccine and Serum Institute, China • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:12 UTC
-
New combo aims to shrink tumors and cut radiation for young cancer patients
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy (gemcitabine and cisplatin) before radiation therapy is safe and effective for children and young adults (up to age 21) with newly diagnosed nasopharyngeal carcinoma. The goal is to see if t…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
Cancer drug nivolumab takes on EBV-Linked tumors in new trial
Disease control Recruiting nowThis phase 2 trial tests whether the drug nivolumab can slow or stop the growth of Epstein-Barr virus (EBV)-positive lymphoproliferative disorders and non-Hodgkin lymphomas. About 40 people aged 12 and older whose cancers have not responded to standard therapy will receive nivolu…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New combo therapy aims to boost survival in hodgkin lymphoma
Disease control Recruiting nowThis phase 3 trial is testing whether adding immunotherapy drugs (brentuximab vedotin and nivolumab) to standard chemotherapy (with or without radiation) improves survival for people aged 5 to 60 with newly diagnosed stage I or II classical Hodgkin lymphoma. About 1,875 participa…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
Personalized chemo boosts CAR T-Cell success in young leukemia patients
Disease control Recruiting nowThis study tests whether giving a personalized dose of the chemotherapy drug fludarabine before CAR T-cell therapy can improve outcomes for children and young adults with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia. About 130 participants will be randomly assign…
Phase: PHASE3 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New hope for tough leukemia: MK-1045 takes on standard therapy
Disease control Recruiting nowThis study compares a new immunotherapy, MK-1045, to the standard drug blinatumomab in people whose B-cell acute lymphoblastic leukemia has returned or stopped responding to treatment. About 340 adults with CD19-positive leukemia will receive one of the two treatments. The goal i…
Phase: PHASE2, PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Blood test could guide anal cancer treatment, reducing side effects
Disease control Recruiting nowThis study tests whether a blood test (ctDNA) can help doctors customize the dose of chemoradiation for people with anal cancer. Depending on how the tumor responds, some patients may get a lower radiation dose to reduce side effects, while others may get a higher dose or an adde…
Phase: PHASE2 • Sponsor: Jennifer Dorth • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug offers hope for lymphoma patients who Can't get transplants
Disease control Recruiting nowThis phase 2 study tests the drug epcoritamab in 30 people with relapsed or refractory large B-cell lymphoma who are not eligible for a stem cell transplant. Epcoritamab is a bispecific antibody that helps the immune system target and kill cancer cells. The main goal is to see ho…
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New 5-Drug combo aims to tackle tough lymphoma
Disease control Recruiting nowThis study tests a combination of five drugs (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, called ViPOR) in adults with B-cell lymphoma that has come back or not responded to prior treatment. The main goal is to check the safety of this drug mix. Up to 155 p…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New STING agonist drug enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial tests the safety of CRD3874-SI, a drug that activates the STING pathway to boost the immune system against cancer. About 81 adults with advanced solid tumors (sarcoma, Merkel cell carcinoma, and others) will receive weekly IV infusions at increasing doses. …
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a blood test and MRI tailor cancer therapy to each patient?
Disease control Recruiting nowThis trial tests whether giving extra chemotherapy or a combination of chemotherapy and immunotherapy after standard treatment can improve outcomes for people with nasopharyngeal carcinoma. The choice of treatment is based on each patient's risk level, determined by changes in a …
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Immunotherapy combo may outperform chemo in rare lymphoma
Disease control Recruiting nowThis Phase 3 trial tests whether an immunotherapy-based regimen (sintilimab, pegaspargase, and anlotinib) works better than standard chemotherapy before a stem cell transplant in people with newly diagnosed, advanced extranodal NK/T-cell lymphoma. Participants are randomly assign…
Phase: PHASE3 • Sponsor: Rong Tao • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New virus therapy takes on advanced cancers in first human trial
Disease control Recruiting nowThis early-phase study tests a new treatment called MQ710, a modified virus injected directly into tumors, alone or with the immunotherapy drug pembrolizumab. It is for people with advanced solid tumors (like skin cancer or head and neck cancer) that have not responded to standar…
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug KUP-101A enters first human tests for advanced skin cancers
Disease control Recruiting nowThis early-stage study tests a new drug called KUP-101A in 21 people with advanced skin cancers (like melanoma or Merkel cell carcinoma) that have not responded to other treatments. The main goals are to find the safest dose and check for side effects. Researchers will also measu…
Phase: PHASE1 • Sponsor: Kupando GmbH • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a new immune drug outsmart Hard-to-Treat tumors?
Disease control Recruiting nowThis trial tests an experimental drug called STAR0602, which is designed to help the immune system attack cancer cells. It is being studied in people with advanced solid tumors that have not responded to standard treatments. The drug is given alone or combined with chemotherapy, …
Phase: PHASE1, PHASE2 • Sponsor: Marengo Therapeutics, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Experimental antibody takes aim at Hard-to-Treat lymphoma
Disease control Recruiting nowThis early-phase trial tests a drug called teclistamab in 30 adults with plasmablastic lymphoma that has returned or not responded to prior treatment. Teclistamab is a bispecific antibody designed to attach to both cancer cells and immune T-cells, helping the immune system attack…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a Tumor-Injected drug combo outlast standard care in advanced sarcoma?
Disease control Recruiting nowThis phase 3 trial is testing whether an investigational drug called INT230-6, which combines three anti-cancer agents and is injected directly into tumors, can help people with advanced soft tissue sarcoma live longer than those receiving standard care. The study enrolls adults …
Phase: PHASE3 • Sponsor: Intensity Therapeutics, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Double immunotherapy may keep nasopharyngeal cancer at bay
Disease control Recruiting nowThis phase II trial tests whether adding the immunotherapy drug relatlimab to standard nivolumab maintenance therapy can extend the time before cancer grows or spreads in patients with recurrent or metastatic nasopharyngeal cancer linked to Epstein-Barr virus. Participants first …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New cocktail aims to tame rare brain cancer
Disease control Recruiting nowThis early-stage trial tests a combination of four drugs—lenalidomide, nivolumab, rituximab, and methotrexate—in people with primary CNS lymphoma, a rare cancer of the brain or spinal cord. The goal is to find the safest dose and see if adding lenalidomide and nivolumab to standa…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New CAR t-cell combo aims to control aggressive leukemia
Disease control Recruiting nowThis study tests a CAR T-cell drug called brexucabtagene autoleucel in 40 adults with B-cell acute lymphocytic leukemia that has come back or is hard to treat. Participants first receive standard chemotherapy drugs to reduce cancer, then get the CAR T-cells. The goal is to see if…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Engineered cells take on hard-to-treat blood cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new approach for people with certain blood cancers (like lymphoma) that have returned or not responded to standard therapy. Participants receive their own immune cells that have been modified to attack cancer cells, along with specially edited stem …
Phase: PHASE1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug cocktail aims to tackle tough blood cancers
Disease control Recruiting nowThis phase II trial is testing a combination of six chemotherapy drugs (clofarabine, etoposide, cyclophosphamide, liposomal vincristine, dexamethasone, and bortezomib) in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, or related cancers that have come back or…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug combo after brain radiation shows promise for lymphoma patients
Disease control Recruiting nowThis early-phase trial tests whether a combination of two drugs (loncastuximab tesirine and rituximab) given after precise radiation to the brain is safe and effective for central nervous system lymphoma. The study enrolls 12 adults whose lymphoma has returned or who cannot recei…
Phase: PHASE1 • Sponsor: University of Utah • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Promising new combo therapy for infant leukemia shows potential
Disease control Recruiting nowThis study tests whether adding two targeted drugs, blinatumomab and venetoclax, to standard chemotherapy can improve outcomes for infants with a type of leukemia called acute lymphoblastic leukemia (ALL). About 153 infants will participate. The goal is to see if these combinatio…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Immunotherapy-Chemo cocktail shows promise for tough hodgkin lymphoma
Disease control Recruiting nowThis phase 2 trial is testing whether adding the immunotherapy drug pembrolizumab to standard GVD chemotherapy can improve outcomes for people with Hodgkin lymphoma that has returned or not responded to initial treatment. About 257 participants will receive up to 4 cycles of the …
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Supercharged immune cells take on tough blood cancers
Disease control Recruiting nowThis study tests a new treatment for people with blood cancers like leukemia, lymphoma, and multiple myeloma that have returned or not responded to treatment. Participants receive chemotherapy followed by specially engineered natural killer (NK) cells from donated cord blood. The…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New CAR-T therapy aims to tackle Hard-to-Treat hodgkin lymphoma
Disease control Recruiting nowThis study tests a new type of immunotherapy called CAR-T cells, which are specially engineered to recognize and attack CD30, a protein found on Hodgkin lymphoma cells. The trial enrolls up to 31 adults whose cancer has returned or not responded to standard treatments. Participan…
Phase: PHASE1, PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a new pill help the immune system fight cancer?
Disease control Recruiting nowThis trial is testing an investigational drug called ARV-6723, given as a pill, in people with advanced solid tumors. The drug is designed to help the immune system recognize and attack cancer cells. The study will test ARV-6723 alone and in combination with pembrolizumab, an imm…
Phase: PHASE1, PHASE2 • Sponsor: Arvinas Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug karonudib tested in blood cancer patients
Disease control Recruiting nowThis early-phase trial tests the safety of a new drug called karonudib in up to 9 adults with blood cancers like leukemia who have no standard treatment options left. The study aims to find a safe dose and look for any signs that the drug works. It is too early to know if karonud…
Phase: PHASE1 • Sponsor: Thomas Helleday Foundation • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a Four-Pronged attack beat brain lymphoma?
Disease control Recruiting nowThis trial is testing whether combining a short course of focused radiation with three drugs—GM-CSF, pomalidomide, and glofitamab—can effectively treat newly diagnosed primary central nervous system diffuse large B-cell lymphoma (PCNSL), a rare and aggressive cancer of the brain …
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Xiamen University • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Could a Lab-Made protein help fight HIV-Related cancer?
Disease control Recruiting nowThis study tests a lab-made human protein called CYT107 in 55 people with HIV and Kaposi sarcoma. The protein aims to boost T cells, which may help shrink cancer tumors. Participants receive weekly injections for up to 4 weeks, with follow-up for 3 years.
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Gene therapy injection takes aim at Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-stage trial tests a single-dose gene therapy called VNX-101 for people with certain blood cancers (like leukemia or lymphoma) that have returned or not responded to standard treatment. The therapy delivers instructions to the body to make a protein that helps immune ce…
Phase: PHASE1, PHASE2 • Sponsor: Vironexis Biotherapeutics Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New combo therapy aims to fight hard-to-treat blood cancers
Disease control Recruiting nowThis early-phase study tests a new treatment for adults with certain types of blood cancer (like lymphoma) that have come back or not responded to standard therapies. The treatment combines a targeted drug (pirtobrutinib) with specially engineered immune cells (CAR T-cells) desig…
Phase: PHASE1 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a Brain-Penetrating drug tackle recurrent CNS lymphoma?
Disease control Recruiting nowThis phase 2 trial is testing whether paxalisib (GDC-0084), an oral drug taken daily, can shrink or control tumors in people with recurrent or refractory primary central nervous system lymphoma (PCNSL) — a rare type of non-Hodgkin lymphoma that starts in the brain or spinal cord.…
Phase: PHASE2 • Sponsor: Lakshmi Nayak, MD • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Blood test may tailor throat cancer treatment, sparing patients from harsh side effects
Disease control Recruiting nowThis trial tests whether a blood test that detects HPV DNA can help doctors personalize treatment for people with HPV-related throat cancer. Participants receive radiation therapy, with or without chemotherapy, but the intensity is adjusted based on their blood test results and c…
Phase: PHASE2 • Sponsor: Jonathan Schoenfeld, MD, MPH • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Promising new combo aims to beat aggressive leukemia
Disease control Recruiting nowThis phase 2 trial is testing a combination of blinatumomab (an immune-boosting drug) with dasatinib or imatinib (targeted pills) and standard chemotherapy for people with a specific type of leukemia called Philadelphia chromosome-positive or Philadelphia chromosome-like B-ALL. T…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New drug mosunetuzumab takes on rituximab in rare lymphoma trial
Disease control Recruiting nowThis phase 2 trial tests whether mosunetuzumab, a newer antibody, works better than the standard rituximab for nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). About 70 patients with untreated or previously treated NLPHL will receive one of the two drugs. The main goal is…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Immunotherapy before surgery: a new hope for HPV throat cancer?
Disease control Recruiting nowThis phase 2 trial is testing whether the immunotherapy drug atezolizumab, given before surgery, can help treat HPV-related throat cancer that can be removed. About 20 adults with stage I oropharyngeal cancer will receive two doses of atezolizumab followed by standard surgery. Th…
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New oral drug takes on tough brain cancer in phase 3 trial
Disease control Recruiting nowThis phase 3 trial is testing whether the oral targeted drug tirabrutinib works better than a standard combination of rituximab and temozolomide for people with relapsed or refractory primary central nervous system lymphoma (PCNSL). About 132 participants will be randomly assigne…
Phase: PHASE3 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New hope for young cancer patients: glofitamab trial targets tough lymphoma
Disease control Recruiting nowThis study tests a drug called glofitamab, which helps the immune system find and kill cancer cells, in children and young adults (ages 6 months to under 30) whose B-cell lymphoma has come back or not responded to treatment. Some participants receive glofitamab alone, while other…
Phase: PHASE1, PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New combo therapy aims to beat leukemia in young adults
Disease control Recruiting nowThis phase III trial is testing whether adding inotuzumab ozogamicin—a drug that targets cancer cells—to standard chemotherapy can improve outcomes for young adults (ages 18-39) newly diagnosed with B-cell acute lymphoblastic leukemia. About 310 participants will be enrolled. The…
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a daily pill keep brain lymphoma at bay after remission?
Disease control Recruiting nowThis trial is testing whether taking tirabrutinib daily can help people with primary central nervous system lymphoma (PCNSL) stay in remission longer after their initial chemotherapy has worked. Participants who have achieved complete remission will be randomly assigned to receiv…
Phase: PHASE2 • Sponsor: Kyorin University • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New combo therapy shows promise for Hard-to-Treat leukemia
Disease control Recruiting nowThis phase II trial is testing a combination of two targeted drugs, inotuzumab ozogamicin and blinatumomab, with or without ponatinib, for adults with a type of leukemia called B-ALL. The study includes newly diagnosed older adults and those whose cancer has returned or not respo…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Could a Two-Drug punch before surgery shrink head & neck tumors?
Disease control Recruiting nowThis study tests whether adding an experimental drug (CDX-1140) to a standard immunotherapy (cemiplimab) before surgery can shrink advanced head and neck cancers more than the immunotherapy alone. About 44 people with stage III-IV head and neck cancer will receive either the comb…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New inhaled drug aims to stop lung infections in vulnerable blood cancer patients
Disease control Recruiting nowThis study tests an experimental inhaled drug called PUL-042 in 100 people with blood cancers or who have had a stem cell transplant and have a viral lung infection. Participants receive either the drug or a placebo three times over six days. The goal is to see if PUL-042 can red…
Phase: PHASE2 • Sponsor: Pulmotect, Inc. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New study targets rare Virus-Driven inflammatory syndrome
Disease control Recruiting nowThis study looks at a newly recognized disease called KSHV Inflammatory Cytokine Syndrome (KICS), caused by a virus that can also lead to certain cancers. Researchers aim to learn more about the disease and test experimental treatments, including antiviral and chemotherapy drugs,…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New hope for rare childhood cancer: drug cocktail aims to shrink tumors and prevent return
Disease control Recruiting nowThis study is for children and young adults (up to age 30) with a rare type of soft tissue cancer called non-rhabdomyosarcoma. It tests whether adding the drugs pazopanib and selinexor to standard chemotherapy can improve outcomes. Participants receive treatment tailored to their…
Phase: PHASE1, PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a smart brain implant outsmart chronic pain?
Disease control Recruiting nowThis trial tests whether a new type of deep brain stimulation (DBS) can better relieve chronic pain that hasn't responded to other treatments. Unlike traditional DBS, which delivers constant stimulation, this approach uses a device that adapts stimulation in real time based on br…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New drug takes aim at Hard-to-Treat sarcoma
Disease control Recruiting nowThis early-stage trial is testing a new drug called REC-617 in 15 people with a rare type of sarcoma (leiomyosarcoma) that has spread or cannot be removed and has not responded to prior treatments. The drug targets a protein (CDK7) that helps cancer cells grow. The main goal is t…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New Dual-Target CAR T-Cell therapy aims to beat relapsed childhood cancers
Disease control Recruiting nowThis study tests a new type of CAR T-cell therapy that targets two proteins, CD19 and CD22, on cancer cells. It is for children and young adults aged 3 to 39 with B-cell cancers like leukemia or lymphoma that have not been cured by standard treatments. Participants receive their …
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Can a common breast cancer drug slow uterine sarcoma?
Disease control Recruiting nowThis phase 2 trial tests whether the drug letrozole can extend the time before uterine leiomyosarcoma returns after initial treatment. About 40 women with early-stage disease will be randomly assigned to take letrozole daily or to be observed without treatment. The main goal is t…
Phase: PHASE2 • Sponsor: GOG Foundation • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Tailored radiation aims to shrink tumors, spare healthy tissue in nasopharyngeal cancer
Disease control Recruiting nowThis phase 3 trial tests whether a personalized radiation plan, which expands the treatment area based on each patient's tumor margins, can control nasopharyngeal cancer as well as the standard approach. The study includes 568 adults with newly diagnosed, non-metastatic disease. …
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Could less radiation be just as effective for HPV throat cancer?
Disease control Recruiting nowThis study tests whether a personalized, lower dose of radiation (guided by a special PET scan) works as well as the standard dose for people with HPV-positive throat cancer. About 291 participants will receive either the lower or standard radiation dose, along with standard chem…
Phase: PHASE3 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Can Long-Acting HIV shots outperform daily pills during lymphoma treatment?
Disease control Recruiting nowThis trial investigates whether long-acting injectable antiretroviral drugs can control HIV better than standard oral pills in adults with AIDS-related lymphoma who are also receiving chemotherapy. Participants will receive one of three HIV treatment strategies—oral pills alone, …
Phase: NA • Sponsor: Shanghai Public Health Clinical Center • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Can less be more? new trial aims to cut harsh side effects in HPV throat cancer treatment
Disease control Recruiting nowThis study is for people with HPV-related throat cancer. After surgery, patients receive lower-than-standard doses of radiation and sometimes chemotherapy, based on their risk level. The goal is to keep cancer from coming back while reducing side effects like weight loss. About 1…
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New combo therapy offers hope for hard-to-treat nose cancer
Disease control Recruiting nowThis study tests a new treatment for people whose nose and throat cancer has returned and cannot be removed with surgery. The treatment combines an immunotherapy drug (PD-1 antibody) with two chemotherapy drugs, followed by targeted radiation. The goal is to see if this approach …
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New drug duo aims to shrink tough cancers
Disease control Recruiting nowThis study tests a new drug called BL-B01D1 combined with an immunotherapy (PD-1 antibody) in people with advanced lung cancer, nasopharyngeal cancer, or other solid tumors that have spread. The goal is to see if the combination can shrink tumors and control the disease. About 57…
Phase: PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase trial tests a new drug called STC-15, either alone or combined with an immunotherapy drug (toripalimab), in people with advanced solid tumors or certain sarcomas. The study aims to check safety and whether the drugs shrink tumors. About 107 participants will be e…
Phase: PHASE1, PHASE2 • Sponsor: STORM Therapeutics LTD • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New drug aims to supercharge immune system against HPV throat cancer
Disease control Recruiting nowThis study tests an experimental drug called CUE-101 in 30 people with HPV16-positive throat cancer. The drug is given before standard treatments like surgery or chemoradiation to see if it safely boosts the body's immune cells to fight the cancer. Researchers will monitor side e…
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New drug combo aims to outsmart kaposi sarcoma tumors
Disease control Recruiting nowThis study tests two drugs, PDS01ADC and M7824, that work with the immune system to fight Kaposi sarcoma (KS), a cancer often linked to HIV or organ transplants. The trial enrolls 80 adults with advanced KS that has not responded well to prior therapy. Participants receive PDS01A…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New antibody drug YK012 takes aim at Hard-to-Treat lymphoma
Disease control Recruiting nowThis early-phase study is testing a new drug called YK012 in 48 adults with relapsed or refractory B-cell non-Hodgkin lymphoma. YK012 is a bispecific antibody designed to help the body's immune T cells recognize and kill cancer B cells. The main goals are to check the drug's safe…
Phase: PHASE1 • Sponsor: Excyte Biopharma Ltd • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New pill takes on brain tumors and metastases in early trial
Disease control Recruiting nowThis study tests an oral drug called NEO212 in people with specific brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control tumor growth. About 134 adults will take NEO212 alone or with sta…
Phase: PHASE1, PHASE2 • Sponsor: Neonc Technologies, Inc. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Can a pill make CAR T-Cell therapy last longer?
Disease control Recruiting nowThis early-phase trial tests whether the drug pomalidomide can improve the effects of CAR T-cell therapy in people with B-cell leukemias or lymphomas that have returned or not responded to treatment. The study will enroll 12 adults who have already received CAR T-cell therapy. Re…
Phase: PHASE1 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Could a 'Sandwich' of drugs beat Full-Course immunotherapy for a tough head and neck cancer?
Disease control Recruiting nowThis phase III trial tests whether a shorter, 'immune sandwich' regimen works as well as full-course immunotherapy for locally advanced nasopharyngeal carcinoma. The experimental group gets induction chemotherapy plus two immune-targeting drugs (toripalimab and nimotuzumab), then…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New drug duo aims to keep advanced nasopharyngeal cancer in check
Disease control Recruiting nowThis Phase III trial tests whether adding an experimental drug called becotatug vedotin to standard anti-PD1 immunotherapy can better control advanced nasopharyngeal carcinoma that has spread or returned. About 86 adults whose cancer has stabilized after initial chemoimmunotherap…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Engineered donor cells take on lymphoma in early trial
Disease control Recruiting nowThis early-phase study tests a new approach for patients with certain lymphomas (Hodgkin, NK/T-cell, and others) that have returned or not responded to treatment. The therapy uses immune cells from healthy donors that are specially trained in the lab to attack cancer cells carryi…
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New antibody combo aims to treat brain lymphoma
Disease control Recruiting nowThis trial investigates a combination of two drugs—tafasitamab, an antibody given by IV, and lenalidomide, an oral medication—for people with relapsed central nervous system (CNS) lymphoma. The study includes up to 35 participants and is the first to test this antibody in CNS lym…
Phase: PHASE1, PHASE2 • Sponsor: James Rubenstein • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Double-Targeting antibody takes on Hard-to-Treat throat cancer
Disease control Recruiting nowThis trial tests a new drug called JS207, a bispecific antibody that targets two proteins (PD1 and VEGF) involved in cancer growth and immune evasion. It is being studied in people with recurrent or metastatic nasopharyngeal carcinoma, a type of throat cancer, who have already tr…
Phase: PHASE2 • Sponsor: Chinese University of Hong Kong • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Engineered immune cells take on tough lymphomas
Disease control Recruiting nowThis phase 2 trial tests a personalized cell therapy called zamtocabtagene autoleucel (MB-CART2019.1) for people with B cell lymphomas that have come back or not responded to standard treatments. Participants receive their own immune cells that have been genetically modified to r…
Phase: PHASE2 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Engineered immune cells take on HIV-Linked cancers in first human trial
Disease control Recruiting nowThis study tests a CAR-T cell therapy (axicabtagene ciloleucel) in 20 HIV-positive adults whose aggressive B-cell lymphoma has come back or stopped responding to standard treatment. The therapy uses a patient's own immune cells, modified to recognize and attack cancer cells. The …
Phase: PHASE1 • Sponsor: AIDS Malignancy Consortium • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Vaccine trains immune system to fight HPV-Positive head and neck tumors
Disease control Recruiting nowThis trial tests a vaccine called BVAC-E6E7 in people with head and neck cancer linked to HPV types 16 or 18 that cannot be removed by surgery or has spread. The vaccine is designed to teach the immune system to attack cancer cells. The study first checks safety and the best dose…
Phase: PHASE1, PHASE2 • Sponsor: Cellid Co., Ltd. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New cell addback could shield kids from deadly infections after transplant
Disease control Recruiting nowThis study tests whether giving children with leukemia a special type of donor immune cell (CD45RA-depleted) after a stem cell transplant can help their immune system recover faster and lower the risk of serious viral or fungal infections. The trial enrolls 50 children under 25 w…
Phase: NA • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Immune booster after standard therapy may stall nasopharyngeal cancer
Disease control Recruiting nowThis phase 2 trial tests whether the immunotherapy drug nivolumab can improve outcomes for people with locally advanced nasopharyngeal carcinoma who still have signs of cancer after standard chemoradiotherapy. About 57 adults aged 19 and older will receive nivolumab infusions eve…
Phase: PHASE2 • Sponsor: Yonsei University • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New hope for kids with tough cancers: immunotherapy drug tested
Disease control Recruiting nowThis study tests pembrolizumab, a drug that helps the immune system fight cancer, in children aged 6 months to 18 years with advanced melanoma, solid tumors, or lymphoma that has spread, returned, or not responded to other treatments. The main goal is to see if the drug can shrin…
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New transplant recipe aims to tame Graft-Versus-Host disease
Disease control Recruiting nowThis study tests a stem cell transplant using a reduced-intensity conditioning regimen (lower doses of chemotherapy and radiation) followed by a donor stem cell infusion. The goal is to treat various blood cancers and blood disorders while lowering the risk of graft-versus-host d…
Phase: PHASE2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Immune booster may strengthen stem cell transplant against hodgkin lymphoma
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to a standard stem cell transplant can help people with Hodgkin lymphoma that has come back or not responded to treatment. Participants receive pembrolizumab before and after their own stem cells are …
Phase: PHASE2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New hope for rare cancers: daratumumab trial targets Hard-to-Treat lymphomas
Disease control Recruiting nowThis phase 2 trial tests the drug daratumumab in 28 adults with three rare and aggressive blood cancers: primary effusion lymphoma, plasmablastic lymphoma, and multicentric Castleman disease. Participants must have failed standard therapy or be unable to receive it. Daratumumab i…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Blood test may let some throat cancer patients skip radiation after surgery
Disease control Recruiting nowThis study is for people with HPV-related throat cancer who have surgery to remove the tumor. Normally, some patients also get radiation afterward to lower the risk of cancer coming back. This trial tests whether it's safe to skip that radiation if a blood test two weeks after su…
Phase: PHASE2 • Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope: drug combo targets HIV-Linked cancers
Disease control Recruiting nowThis early-stage trial tests whether adding the drug pomalidomide to standard chemotherapy (with or without rituximab) is safe and effective for people with HIV who have aggressive B-cell non-Hodgkin lymphoma. About 25 adults with high-risk features will receive up to 6 cycles of…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for hepatitis delta: can switching drugs clear the virus?
Disease control Recruiting nowThis study tests whether switching from the current drug bulevirtide to a new drug called brelovitug can better control chronic hepatitis Delta. About 120 adults who have been on bulevirtide for at least 6 months will take brelovitug for 24 weeks. The main goal is to see if the v…
Phase: PHASE2, PHASE3 • Sponsor: Mirum Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Supercharged cord blood cells take on resistant blood cancers
Disease control Recruiting nowThis early-stage trial tests a new type of immune cell therapy for people with several kinds of blood cancers that have come back or stopped responding to treatment. The therapy uses natural killer (NK) cells from donated cord blood, which are genetically modified to better recog…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Engineered immune cells take aim at stubborn blood cancers
Disease control Recruiting nowThis study tests a new type of immunotherapy called CAR-T cells that are designed to recognize and attack cancer cells carrying a protein called CD7. It includes people with several blood cancers, such as T-cell acute lymphoblastic leukemia and acute myeloid leukemia. The goal is…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug combo aims to boost radiation success in EBV-related throat cancer
Disease control Recruiting nowThis study tests whether giving three drugs (gemcitabine, docetaxel, and toripalimab) before standard radiation can safely improve outcomes for people with a specific throat cancer caused by the Epstein-Barr virus. About 24 adults with advanced but not spread cancer will receive …
Phase: PHASE2 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New CAR-T therapy aims to keep High-Risk leukemia in remission
Disease control Recruiting nowThis study tests a new type of immunotherapy called CD22/CD19 dual-target CAR-T cells in people with high-risk B-cell acute lymphoblastic leukemia (B-ALL) who have already achieved their first remission after standard treatment. The goal is to see if this therapy can safely and e…
Phase: PHASE1, PHASE2 • Sponsor: Liping Dou • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug combo aims to make stem cell transplants safer for blood cancer patients
Disease control Recruiting nowThis Phase 2 trial is testing a stem cell transplant from a donor for people with various blood cancers and bone marrow disorders. The transplant uses strong chemotherapy or radiation to wipe out the diseased marrow, then replaces it with healthy donor cells. A new combination of…
Phase: PHASE2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Engineered immune cells take on stubborn lymphoma
Disease control Recruiting nowThis study tests a new approach using a mix of gene-modified immune cells (CAR-T cells) that target multiple proteins found on B cell lymphoma cells. The goal is to see if this combination is safe and can shrink tumors in patients whose cancer has not responded to standard treatm…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Custom-Made cancer vaccine shows promise in advanced tumors
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab. The goal is to see if the combination is safe and helps the immune system attack advanced solid tumors. About 132 people with various advanc…
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New universal CAR t therapy targets tough blood cancers
Disease control Recruiting nowThis early-stage trial tests a new type of immune cell therapy (called universal CAR T cells) for people with certain blood cancers, including T-cell leukemia and lymphoma. The therapy targets a protein called CD7 found on cancer cells. The study will check if the treatment is sa…
Phase: PHASE1 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo targets Hard-to-Treat lymphomas
Disease control Recruiting nowThis study tests a new drug called AZD3470, alone or with pembrolizumab (Keytruda), in people with certain blood cancers like lymphoma. The goal is to check safety, side effects, and whether the drug shrinks tumors. About 161 adults and teens will take part.
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New combo therapy aims to wipe out leukemia cells for good
Disease control Recruiting nowThis early-stage trial tests a combination therapy for B-cell acute lymphoblastic leukemia (B-ALL). It uses specially engineered immune cells (CAR-T cells and CTLs) followed by a dendritic cell vaccine to target multiple cancer markers. The goal is to achieve a very deep remissio…
Phase: PHASE1 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Two-Drug combo aims to tackle Hard-to-Treat hodgkin lymphoma
Disease control Recruiting nowThis phase 2 trial tests whether combining pembrolizumab (Keytruda) with bendamustine (Treanda) is safe and effective for people with Hodgkin lymphoma that has come back or is no longer responding to standard treatments. About 40 adults will receive the drug combination, and rese…
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Second-Chance CAR-T: could Off-Spec cells still fight cancer?
Disease control Recruiting nowThis phase 3 trial is testing a CAR-T cell therapy called tisagenlecleucel that didn't quite meet commercial release standards. It's for people with B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma who have no other approved options. The study will check if th…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Home-Based program aims to help long COVID patients breathe easier and move more
Disease control Recruiting nowThis study tests a comprehensive, remotely delivered care program for people aged 40 and older with Long COVID who have ongoing heart or lung symptoms like fatigue, shortness of breath, or chest pain. The program includes medication review, mental health support, telehealth coach…
Phase: NA • Sponsor: University of Tasmania • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope: drug before surgery may stop merkel cell cancer spread
Disease control Recruiting nowThis study tests whether giving the drug cemiplimab before lymph node surgery can prevent Merkel cell carcinoma from spreading to nearby lymph nodes. About 135 adults with early-stage cancer will receive either the drug or a placebo before their scheduled biopsy. The goal is to s…
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New combo attack on rare blood cancer shows promise in early trial
Disease control Recruiting nowThis study tests two drugs, tislelizumab and zeprumetostat, together in people with a rare type of lymphoma that has come back or not responded to treatment. About 107 adults will take part to see if the combination is safe and shrinks tumors. The goal is to control the cancer, n…
Phase: PHASE1, PHASE2 • Sponsor: Rong Tao • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug trial aims to slow rare Cancer's spread
Disease control Recruiting nowThis study tests a drug called zanzalintinib (XL092) in 29 people with advanced leiomyosarcoma that has spread or cannot be removed by surgery. The drug works by blocking signals that help cancer cells grow. The goal is to see if it can slow the cancer's progression longer than c…
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could less radiation be just as good for some throat cancers?
Disease control Recruiting nowThis study looks at whether people with a type of throat cancer linked to the Epstein-Barr virus can safely receive lower doses of radiation after initial chemotherapy. The goal is to see if reducing radiation can still control the cancer while causing fewer long-term side effect…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New CAR-T therapy aims to keep leukemia in remission
Disease control Recruiting nowThis study tests a new immune cell therapy (dual-target CD22/CD19 CAR-T cells) as a consolidation treatment for people with standard-risk B-cell acute lymphoblastic leukemia (B-ALL) who are in remission. The goal is to see if it is safe and can help prevent the cancer from coming…
Phase: PHASE1, PHASE2 • Sponsor: Liping Dou • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Alpha radiation seeds target tumors from the inside
Disease control Recruiting nowThis study tests a device called DaRT that delivers a unique type of radiation (alpha particles) directly into tumors. It is designed for people with certain skin cancers, mouth cancers, or soft tissue sarcomas that are accessible for direct injection. The goal is to see if this …
Phase: NA • Sponsor: Alpha Tau Medical LTD. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug AB821 enters first human tests for advanced melanoma
Disease control Recruiting nowThis early-stage trial is testing a new drug called AB821 in 50 adults with advanced melanoma or other solid tumors that respond to immune therapies. The main goal is to check safety and find the right dose. Participants receive AB821 by IV every 2 or 3 weeks for up to two years.
Phase: PHASE1 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for hard-to-treat brain cancer: combo therapy enters trial
Disease control Recruiting nowThis study tests a new drug called epcoritamab, given with two other drugs (lenalidomide and rituximab), for people whose primary CNS lymphoma has returned or stopped responding to treatment. The goal is to see if this combination can shrink or control the cancer. About 60 adults…
Phase: PHASE2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Cancer-Killing virus shows promise in early trial for advanced tumors
Disease control Recruiting nowThis early-phase trial is testing a new treatment called MEM-288, a virus designed to infect and kill cancer cells while also boosting the immune system. The study involves 40 adults with advanced solid tumors, including lung, skin, and breast cancers, who have not responded to s…
Phase: PHASE1 • Sponsor: Memgen, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
Experimental immune therapy aims to tackle HPV cancers before standard care
Disease control Recruiting nowThis study tests whether a single infusion of a patient's own genetically engineered immune cells (E7 TCR-T cells) can shrink or eliminate HPV-related cancers before the patient receives standard treatment like chemo-radiation or surgery. The trial enrolls 15 adults with advanced…
Phase: PHASE1, PHASE2 • Sponsor: Christian Hinrichs • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Two-Drug cocktail targets Hard-to-Treat hodgkin lymphoma
Disease control Recruiting nowThis study tests two drugs—nivolumab and ruxolitinib—together in people whose Hodgkin lymphoma has returned or not responded to treatment. The goal is to find the safest dose of ruxolitinib when combined with a fixed dose of nivolumab, and to see if the combination can control th…
Phase: PHASE1, PHASE2 • Sponsor: Veronika Bachanova • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope for hepatitis d: libevitug enters final testing phase
Disease control Recruiting nowThis Phase 3 trial is testing a new drug called libevitug in 160 people with chronic hepatitis D, a serious liver infection. The goal is to see if libevitug can lower the virus in the blood and improve liver health. Participants receive the drug by IV infusion, and the study comp…
Phase: PHASE3 • Sponsor: Huahui Health • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Engineered t cells take on lymphoma in early trial
Disease control Recruiting nowThis early-phase study tests a new treatment for people with Hodgkin or non-Hodgkin lymphoma that has returned or not responded to standard therapy. The treatment uses the patient's own T cells, which are genetically modified to recognize and attack cancer cells carrying the CD30…
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Supercharged immune cells take on HPV cancers
Disease control Recruiting nowThis study tests a new immunotherapy for people with advanced HPV-related cancers, such as cervical, throat, anal, and penile cancers. Participants receive specially engineered immune cells designed to attack cancer cells carrying the HPV16 virus. The goal is to see if this treat…
Phase: PHASE2 • Sponsor: Christian Hinrichs • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug cocktail targets rare, aggressive cancer
Disease control Recruiting nowThis phase 2 trial is testing whether combining two chemotherapy drugs—Abraxane and liposomal doxorubicin—can shrink tumors in people with advanced or unresectable angiosarcoma, a rare and aggressive cancer of blood vessels. The study will enroll 69 patients who have already trie…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Could less radiation be enough for some lymphoma patients?
Disease control Recruiting nowThis study looks at whether a lower dose of radiation can safely prevent cancer from returning in people with early-stage nasal-type NK/T-cell lymphoma who have already had a complete response to chemotherapy. Participants receive 45 Gy of radiation over five weeks, targeting the…
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for tough lymphomas: balstilimab trial opens
Disease control Recruiting nowThis study tests a drug called balstilimab in 20 adults with certain lymphomas (classical Hodgkin lymphoma or primary mediastinal B-cell lymphoma) that have returned or not responded to standard treatments. Participants receive the drug every 3 weeks to see if it shrinks tumors a…
Phase: PHASE2 • Sponsor: Immune Oncology Research Institute • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New risk model may let some NPC patients avoid unnecessary chemo
Disease control Recruiting nowThis study tests a personalized approach for people with advanced nasopharyngeal cancer. After standard chemoradiation, some patients get extra therapy to prevent the cancer from returning. But this extra therapy can cause side effects. The trial uses a new risk model (RAIRI) to …
Phase: PHASE3 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New cell therapy takes on hard-to-treat brain lymphoma in early trial
Disease control Recruiting nowThis early-phase study tests a personalized cell therapy called MB-CART19.1 for people with central nervous system lymphoma (CNSL) that has returned or not responded to prior treatments. The therapy uses the patient's own immune cells, modified to attack the cancer, and is made o…
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New hope for Hard-to-Treat brain cancer: targeted radiation trial launches
Disease control Recruiting nowThis early-phase study tests a new drug called [90Y]Y-PentixaTher for people with central nervous system (CNS) lymphoma that has come back or not responded to standard treatments. The drug delivers radiation directly to cancer cells. About 15 participants will receive one intrave…
Phase: PHASE1, PHASE2 • Sponsor: Pentixapharm AG • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New transplant method aims to cut dangerous side effects in blood cancer patients
Disease control Recruiting nowThis study tests a stem cell transplant method that removes certain immune cells (T-cells and B-cells) from the donor cells. The goal is to reduce graft-versus-host disease, a serious complication where donor cells attack the patient's body. The trial includes 20 children and you…
Phase: PHASE2 • Sponsor: University of Florida • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New formula aims to help long COVID sufferers walk farther
Disease control Recruiting nowThis study tests a new supplement called PNMR in 82 adults with long COVID. Participants either take PNMR plus standard care or standard care alone for 6 weeks. The main goal is to see if PNMR helps people walk farther in a 6-minute test. All participants also get diet and lifest…
Phase: PHASE2 • Sponsor: ParagonClinicals Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New combo injection targets Hard-to-Treat head and neck tumors
Disease control Recruiting nowThis early-phase trial is testing a new approach for people with head and neck cancer that has returned or spread after standard chemotherapy. The treatment combines a gene therapy injection (EDS01) given directly into a tumor with an immunotherapy drug (toripalimab) given throug…
Phase: PHASE1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New cocktail of drugs takes on rare brain cancer
Disease control Recruiting nowThis phase 2 trial tests a combination of four drugs—pirtobrutinib, sintilimab, rituximab, and high-dose methotrexate—as a first treatment for adults with newly diagnosed primary central nervous system lymphoma (PCNSL). About 77 participants will choose either this experimental c…
Phase: PHASE2 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Diet and exercise may ease long COVID symptoms in obese veterans
Disease control Recruiting nowThis study looks at how obesity affects recovery from post-COVID conditions in older Veterans. Researchers will test if a weight loss program with diet and exercise can reduce inflammation and improve physical function and quality of life. The study involves 150 Veterans, some wi…
Phase: NA • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New hope for rare cancer: ivonescimab trial targets leiomyosarcoma
Disease control Recruiting nowThis study tests whether the drug Ivonescimab can safely shrink or control advanced leiomyosarcoma, a rare soft-tissue cancer. About 20 adults who have already tried 1-3 prior treatments will receive the drug. The goal is to see if it slows tumor growth with few side effects.
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Can a two-drug combo beat the HTLV-1 virus?
Disease control Recruiting nowThis Phase 2 trial compares the drug dolutegravir alone versus dolutegravir combined with tenofovir in 146 adults with HTLV-1 infection and related symptoms. The main goal is to see if the combination lowers the virus level more effectively and improves pain, spasticity, and musc…
Phase: PHASE2 • Sponsor: Carlos Brites • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Brain cancer breakthrough? CAR t cells injected directly into fluid around brain in new trial
Disease control Recruiting nowThis early-phase trial tests a new approach to treat central nervous system (CNS) lymphoma by injecting specially engineered immune cells (CAR T cells) directly into the fluid surrounding the brain. The study involves 20 participants and aims to find the safest dose while monitor…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New biologic JLM019 enters human testing for advanced cancers
Disease control Recruiting nowThis early-phase study is testing a new biologic drug called JLM019 in adults with advanced solid tumors or lymphomas that have come back or not responded to treatment. The drug is given as a weekly intravenous infusion, and the main goals are to check its safety, find the right …
Phase: PHASE1 • Sponsor: Jecho Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo tackles rare, aggressive lymphoma
Disease control Recruiting nowThis early study tests adding daratumumab, an antibody that targets a protein on cancer cells, to standard chemotherapy for people with newly diagnosed plasmablastic lymphoma, a rare and fast-growing cancer. The trial includes up to 15 participants, with or without HIV. The main …
Phase: EARLY_PHASE1 • Sponsor: AIDS Malignancy Consortium • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Triple-Target CAR T-Cells offer new hope for tough blood cancers
Disease control Recruiting nowThis early-stage trial tests a new type of cell therapy for people with certain blood cancers (like lymphoma, leukemia) that have returned or stopped responding to standard treatments. The therapy uses a patient's own immune cells, which are genetically modified to recognize and …
Phase: PHASE1 • Sponsor: Sumithira Vasu • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New antibody could tame dual hepatitis b and d infection
Disease control Recruiting nowThis early-stage trial tests a lab-made antibody (HepB mAb19) in 15 people with chronic hepatitis D, a serious liver infection that requires hepatitis B to survive. The goal is to see if the antibody is safe and can lower virus levels, potentially reducing the risk of liver damag…
Phase: PHASE1 • Sponsor: Aarhus University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New hope for rare cancer: targeted drug afatinib tested in fanconi anemia patients
Disease control Recruiting nowThis study tests a drug called afatinib in 25 adults with Fanconi anemia who have advanced head and neck cancer that cannot be removed by surgery. Afatinib is a pill that blocks a protein helping cancer grow. The goal is to see if it can shrink tumors and control the disease. Res…
Phase: PHASE1, PHASE2 • Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug cocktail targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new antibody called HMBD-001 combined with two existing cancer drugs (cetuximab and docetaxel) in people with advanced squamous cell cancers of the lung, head and neck, esophagus, cervix, or skin. The goal is to see if the combination is safe and can shrink tum…
Phase: PHASE1, PHASE2 • Sponsor: Hummingbird Bioscience • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New hope for hodgkin lymphoma: maintenance drug after transplant
Disease control Recruiting nowThis study tests whether a drug called a PD-1 inhibitor can help keep Hodgkin lymphoma from coming back after a stem cell transplant. It is for people whose lymphoma returned or did not respond to earlier treatments. About 83 adults will receive the drug as maintenance therapy an…
Phase: PHASE2 • Sponsor: St. Petersburg State Pavlov Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Could a pill that blocks estrogen help fight rare uterine cancers?
Disease control Recruiting nowThis phase 2 trial is testing elacestrant, a pill that breaks down estrogen receptors, in 30 people with advanced uterine sarcomas that are fueled by estrogen. The goal is to see if the drug can shrink tumors or slow their growth. Participants must have tumors that strongly expre…
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New cocktail aims to shrink brain tumors
Disease control Recruiting nowThis study tests a combination of five drugs (R-PMDT) in 33 people newly diagnosed with primary central nervous system lymphoma, a rare brain cancer. The goal is to see how many patients' tumors shrink or disappear after six cycles of treatment. Researchers will also track how lo…
Phase: PHASE2 • Sponsor: Zou Dehui • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Could chemo before surgery beat sarcoma? new trial aims to find out
Disease control Recruiting nowThis study is for people with a rare, high-risk cancer called retroperitoneal sarcoma. It compares two approaches: getting chemotherapy before surgery versus surgery alone. The goal is to see if the chemo-first approach helps prevent the cancer from coming back. About 250 partici…
Phase: PHASE3 • Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Could a Low-Dose immune drug ease long COVID symptoms?
Disease control Recruiting nowThis study tests whether a low dose of sirolimus (rapamycin), a drug that calms the immune system, can help adults with Long COVID feel better. Eighty participants will take either sirolimus or a placebo pill once a week for 12 weeks. The main goal is to see if the drug improves …
Phase: PHASE3 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Heart shield for young cancer survivors: new study tests dexrazoxane
Disease control Recruiting nowThis study looks at whether a drug called dexrazoxane can help prevent heart damage in children and teens who have been treated for certain cancers like leukemia, lymphoma, and osteosarcoma. Researchers will measure heart function and blood markers in 420 survivors to see if dexr…
Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Could less radiation be just as effective for HPV+ throat cancer?
Disease control Recruiting nowThis study is testing whether a lower dose of radiation (30 Gy) can safely treat HPV-positive oropharyngeal cancer while reducing side effects. About 31 adults with this type of throat cancer will receive the reduced radiation along with standard chemotherapy. The main goal is to…
Phase: PHASE2 • Sponsor: Sara Medek • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug combo aims to keep High-Risk nasopharyngeal cancer at bay
Disease control Recruiting nowThis phase 3 trial tests whether adding toripalimab (an immunotherapy) to capecitabine (a chemotherapy pill) as maintenance therapy works better than capecitabine alone for people with high-risk nasopharyngeal carcinoma. The study enrolls 264 adults aged 18-70 who have completed …
Phase: PHASE3 • Sponsor: Jiangxi Provincial Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New hope for kids with tough cancers: targeted drug trial launches
Disease control Recruiting nowThis study tests a new drug called Becotatug Vedotin in children aged 2 to 18 with certain solid tumors that have come back or spread. The drug targets a protein called EGFR found on many cancer cells. The main goal is to see if the drug is safe and to find the best dose, while a…
Phase: PHASE1 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New stem cell transplant method aims to cut complications in young blood cancer patients
Disease control Recruiting nowThis pilot study tests a stem cell transplant method that removes specific immune cells (alpha/beta T cells and B cells) from the donor cells before transplant. The goal is to reduce the risk of graft-versus-host disease, a serious complication, while still allowing the transplan…
Phase: NA • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New cocktail targets brain lymphoma: early trial launches
Disease control Recruiting nowThis early-stage trial tests whether adding the targeted drug zanubrutinib to a standard chemotherapy regimen (Pola-R-CHP plus high-dose methotrexate) is safe for people with large B-cell lymphoma that has spread to the central nervous system (brain or spinal cord). About 20 adul…
Phase: PHASE1 • Sponsor: Juan P. Alderuccio, MD • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Double-Barreled attack: CAR-T plus stem cell transplant takes on aggressive lymphoma
Disease control Recruiting nowThis study tests a powerful two-step approach for people with a fast-growing type of lymphoma that has not responded to standard treatments. First, patients receive a CAR-T cell therapy (engineered immune cells) followed by a stem cell transplant with high-dose chemotherapy. The …
Phase: PHASE2 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Cord blood transplant offers hope for young blood cancer patients
Disease control Recruiting nowThis study tests whether a cord blood transplant can help children and young adults (up to age 26) with blood cancers like leukemia and lymphoma. Participants receive the transplant as their first or second treatment. The main goal is to see how many are cancer-free one year afte…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New Dual-Target CAR-T therapy takes on tough blood cancers
Disease control Recruiting nowThis early-stage trial tests a new treatment called DuoCAR20.19.22-D95 for adults with B-cell lymphoma or leukemia that has returned or not responded to standard therapy. The treatment uses a patient's own immune cells, which are modified in the lab to better recognize and attack…
Phase: PHASE1 • Sponsor: University of Kansas Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Could a common numbing drug help fight throat cancer?
Disease control Recruiting nowThis early-stage trial is testing whether injecting the local anesthetic lidocaine into HPV-related throat tumors before robotic surgery is safe and might help destroy more cancer cells. About 30 adults with HPV-positive oropharyngeal cancer will receive the injection during a ro…
Phase: PHASE1 • Sponsor: Ryan Carey • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New triple therapy aims to control advanced nose cancer
Disease control Recruiting nowThis study tests a combination of three drugs—an EGFR antibody, a PD-1 inhibitor, and chemotherapy—in people whose nasopharyngeal cancer has returned or spread. The goal is to see if this mix can slow or stop the cancer from growing. About 148 adults aged 18-75 who have not had p…
Phase: PHASE1, PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New hope for tough nasopharyngeal cancer: Triple-Drug combo trial launches
Disease control Recruiting nowThis study tests a combination of three drugs (sintilimab, anlotinib, and chemotherapy) in 33 adults with recurrent or metastatic nasopharyngeal cancer that has not responded to prior immunotherapy. The goal is to see if this combo can shrink tumors or control the disease. Partic…
Phase: PHASE2 • Sponsor: Ming-Yuan Chen • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Can better nutrition improve outcomes for head and neck cancer patients?
Disease control Recruiting nowThis phase 3 trial tests whether a structured nutrition plan (including supplements, feeding tubes, or IV nutrition) helps malnourished patients with advanced nasopharyngeal carcinoma maintain weight and improve their prognosis. About 266 participants will receive either standard…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Nasal spray vaccine plus immunotherapy shows promise in early throat cancer trial
Disease control Recruiting nowThis early-phase trial is testing whether a nasal spray vaccine (WSK-IM05) combined with an immunotherapy drug (tislelizumab) can safely shrink HPV-positive throat tumors before surgery. Nine adults with newly diagnosed, resectable HPV-positive oropharyngeal cancer will receive t…
Phase: PHASE1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Radiation and immunotherapy combo shows promise for advanced nasopharyngeal cancer
Disease control Recruiting nowThis phase II trial is testing whether combining two types of radiation (SBRT and low-dose radiation) with an immunotherapy drug (toripalimab) and chemotherapy can help control recurrent or metastatic nasopharyngeal carcinoma. The study will enroll 148 participants who have not r…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug combo could shrink tumors and reduce radiation side effects in nose cancer
Disease control Recruiting nowThis phase 3 trial tests whether adding an immunotherapy drug (cadonilimab) and low-dose radiation to standard chemotherapy can improve outcomes for people with advanced nasopharyngeal cancer. About 380 participants will be randomly assigned to receive either the new combination …
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Immunotherapy combo aims to beat back recurrent nasopharyngeal cancer
Disease control Recruiting nowThis phase 3 trial tests whether adding an immunotherapy drug called toripalimab to standard chemoradiotherapy helps people with recurrent nasopharyngeal carcinoma live longer. About 212 participants whose cancer has returned after prior treatment and who cannot have surgery will…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Immunotherapy boost may improve outcomes in returning throat cancer
Disease control Recruiting nowThis phase 3 trial tests whether adding an immunotherapy drug (PD-1 antibody) to standard chemoradiotherapy helps people with recurrent nasopharyngeal carcinoma live longer. About 212 participants whose cancer has returned after prior treatment and cannot be surgically removed wi…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New surgery technique could improve survival in recurrent throat cancer
Disease control Recruiting nowThis study compares two surgical techniques for treating nasopharyngeal cancer that has come back after radiation. 500 participants will be randomly assigned to receive either low-temperature plasma ablation or high-frequency electrocautery. The goal is to see which method leads …
Phase: NA • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New trial aims to tame transplant complications in blood cancer patients
Disease control Recruiting nowThis phase II trial tests different drug combinations to prevent graft-versus-host disease (GVHD) in 400 blood cancer patients receiving stem cell transplants from unrelated donors. Participants will receive either thymoglobulin or a combination of cyclophosphamide with other imm…
Phase: PHASE2 • Sponsor: University of Birmingham • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Could less radiation be enough for HPV throat cancer?
Disease control Recruiting nowThis study is testing whether a reduced dose of radiation can safely treat HPV-positive oropharyngeal (throat) cancer. About 111 patients will receive a lower total radiation dose than usual, with some also getting chemotherapy if needed. The goal is to see if this approach keeps…
Sponsor: University of California, Irvine • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New combo therapy aims to beat leukemia without harsh chemo
Disease control Recruiting nowThis phase 2 trial is testing a new treatment strategy for adults newly diagnosed with a type of blood cancer called B-cell acute lymphoblastic leukemia (B-ALL). The approach combines a reduced-dose chemotherapy with a full course of the immunotherapy drug blinatumomab, and may a…
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New immunotherapy combo aims to boost hodgkin lymphoma remission
Disease control Recruiting nowThis Phase 2 trial tests whether adding the immunotherapy drug penpulimab to standard AVD chemotherapy improves outcomes for people with newly diagnosed advanced classic Hodgkin lymphoma. About 108 adults will receive either concurrent or sequential treatment over several cycles.…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New combo therapy aims to halt spread of nasopharyngeal cancer
Disease control Recruiting nowThis phase 3 trial tests whether adding a precise form of radiation (SBRT) to the immunotherapy drug camrelizumab helps control cancer better than camrelizumab alone in people with nasopharyngeal cancer that has spread to a few spots (oligometastatic). About 188 adults whose prim…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Immunotherapy cocktail takes on tough throat cancer
Disease control Recruiting nowThis study tests whether adding an immunotherapy drug (penpulimab) to standard chemotherapy and radiation, followed by maintenance immunotherapy, works better than the usual maintenance drug capecitabine for people with high-risk nasopharyngeal cancer. About 142 participants with…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for hodgkin lymphoma: targeted drug combo shows promise in early trial
Disease control Recruiting nowThis phase 2 trial is testing whether a combination of drugs called BV-AVD works well for people with newly diagnosed, early-stage bulky Hodgkin lymphoma. The study uses PET scans to guide treatment and includes about 71 participants. The goal is to see if this approach can stop …
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New cell therapy CT1182 takes on tough lymphoma
Disease control Recruiting nowThis early-phase study tests a new treatment called CT1182 for people with B-cell non-Hodgkin lymphoma that has come back or not responded to standard therapy. About 24 participants will receive the treatment to see if it is safe and how well it works. The goal is to find the bes…
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could less radiation be just as good for HPV throat cancer?
Disease control Recruiting nowThis study is testing whether a much lower dose of radiation (30 Gy) combined with standard chemotherapy can control HPV-positive throat cancer as well as the usual high dose (70 Gy). The goal is to reduce side effects from radiation while still keeping the cancer from coming bac…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug combo aims to stop brain lymphoma from returning
Disease control Recruiting nowThis phase 2 trial is testing whether a two-year maintenance treatment with lenalidomide and rituximab can prevent relapse in patients with primary central nervous system lymphoma who have responded to initial chemotherapy but are not eligible for a stem cell transplant. The stud…
Phase: PHASE2 • Sponsor: Kim, Seok Jin • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug combo aims to tame stem cell transplant complications
Disease control Recruiting nowThis early-phase trial tests whether two drugs, ruxolitinib and abatacept, can prevent graft-versus-host disease (GVHD) and cytokine release syndrome in people receiving stem cell transplants from half-matched donors. About 41 adults with blood cancers will take these drugs aroun…
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Radioactive drug plus immunotherapy shows promise for rare skin cancer
Disease control Recruiting nowThis study tests a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system fight cancer) and lutetium Lu 177 dotatate (a radioactive drug that kills cancer cells)—in 18 adults with Merkel cell carcinoma. The goal is to see if the combination can shri…
Phase: PHASE2 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for rare lymphomas: drug that blocks JAK protein under study
Disease control Recruiting nowThis study tests the drug ruxolitinib in people with T or NK cell lymphoma that has come back or not responded to prior treatment. Ruxolitinib works by blocking a protein called JAK, which helps these cancer cells survive. The goal is to see if the drug can shrink tumors or contr…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New CAR-T therapy aims to save kids with Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests a new type of CAR-T cell therapy, called UCD19 CAR-T, in children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) or B-cell non-Hodgkin lymphoma (B-NHL) that has come back or not responded to standard treatment. The therapy is made locally to sp…
Phase: PHASE1, PHASE2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New pill aims to tame advanced lymphomas in early trial
Disease control Recruiting nowThis early-phase study tests an experimental oral drug called AUR108 in adults with relapsed advanced lymphomas. The main goals are to check the drug's safety, find the right dose, and see how the body processes it. About 40 participants will take the pill, and researchers will m…
Phase: PHASE1 • Sponsor: Aurigene Discovery Technologies Limited • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Could less radiation be enough for HPV throat cancer? new trial aims to find out.
Disease control Recruiting nowThis study is testing whether people with early-stage HPV-positive throat cancer can be treated with radiation alone at a lower dose, instead of the usual full-dose radiation plus chemotherapy. The goal is to see if this gentler approach can keep the cancer from coming back while…
Phase: NA • Sponsor: Georgetown University • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New Gene-Modified immune cells take on tough lymphoma
Disease control Recruiting nowThis study tests a new treatment called TranspoCART19 for people with B-cell lymphoma that has come back or not responded to standard therapy. The treatment uses a patient's own immune cells, which are genetically modified to better recognize and attack cancer cells. The trial wi…
Phase: PHASE1, PHASE2 • Sponsor: Instituto de Investigación Biomédica de Salamanca • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New pill combo shows promise for tough brain cancer
Disease control Recruiting nowThis study tests an experimental oral drug called emavusertib (CA-4948), taken alone or with ibrutinib, in adults with relapsed or refractory primary central nervous system lymphoma (PCNSL). The trial has multiple parts to find the safest dose and see if the drug shrinks tumors. …
Phase: PHASE1, PHASE2 • Sponsor: Curis, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New combo therapy aims to keep lymphoma at bay after transplant
Disease control Recruiting nowThis study is testing whether a drug called polatuzumab vedotin can safely help control lymphoma after a stem cell transplant. About 20 people with B-cell or Hodgkin lymphoma who have had a relapse or not responded to prior treatment will receive the drug if their disease is stab…
Phase: PHASE1, PHASE2 • Sponsor: New York Medical College • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New cocktail of drugs shows promise for deadly brain cancer
Disease control Recruiting nowThis phase 2 trial tests a combination of three drugs—pomalidomide, tislelizumab, and selinexor—in 43 people with relapsed or refractory primary central nervous system lymphoma. The goal is to see if this cocktail can shrink tumors and improve survival. All participants receive t…
Phase: PHASE2 • Sponsor: Beijing Tongren Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New hope for rare cancers: immunotherapy drug targets tumors regardless of origin
Disease control Recruiting nowThis study tests the drug nivolumab in people with advanced rare cancers that have a specific marker (PD-L1). The goal is to see if the drug can shrink or control the tumors when other treatments have stopped working. Up to 28 adults will receive treatment for up to 12 months, an…
Phase: PHASE2 • Sponsor: Instituto do Cancer do Estado de São Paulo • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Blood filtering shows promise for chronic fatigue sufferers
Disease control Recruiting nowThis study looks at a blood-filtering procedure called immunoadsorption (IA) in 50 people with ME/CFS or Post-COVID syndrome who have certain autoantibodies. The goal is to see if removing these antibodies improves symptoms like severe fatigue and brain fog. Researchers will trac…
Sponsor: Charite University, Berlin, Germany • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New drug combo shows promise for rare, aggressive blood cancer
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug sintilimab to standard chemotherapy can help people with a rare and aggressive type of lymphoma (NK/T-cell lymphoma) that has spread. About 84 newly diagnosed patients will be randomly assigned to receive either the combinati…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New combo therapy aims to keep High-Risk nasopharyngeal cancer at bay
Disease control Recruiting nowThis phase 2 trial is testing whether a year-long combination of tislelizumab (an immunotherapy) and low-dose capecitabine (a chemotherapy pill) can prevent cancer relapse in 53 patients with high-risk nasopharyngeal carcinoma. Participants have already received standard chemothe…
Phase: PHASE2 • Sponsor: National Cancer Centre, Singapore • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug may keep T-Cell lymphoma at bay after transplant
Disease control Recruiting nowThis phase II trial is testing whether the drug ruxolitinib, taken as a daily pill after a stem cell transplant, can help prevent T-cell lymphoma from coming back and reduce the risk of graft-versus-host disease (GVHD). The study will enroll 44 adults with various T-cell lymphoma…
Phase: PHASE2 • Sponsor: Jonathan Brammer • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Vitamin c boost: could high doses help chemo fight tough blood cancers?
Disease control Recruiting nowThis study tests whether adding high-dose vitamin C (ascorbic acid) to standard chemotherapy can help kill cancer cells better in people with certain blood cancers that have returned or not responded to treatment. It includes adults with relapsed or refractory lymphoma, clonal cy…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug combo under watch for Kids' lymphoma
Disease control Recruiting nowThis study tracks side effects of the drug ADCETRIS (brentuximab vedotin) when given with standard chemotherapy to children and teenagers with untreated CD30-positive Hodgkin lymphoma. The main focus is on serious side effects like low blood counts, nerve damage, and lung problem…
Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Electric shocks + chemo: new hope for inoperable tumors?
Disease control Recruiting nowThis study tests a treatment called electrochemotherapy for people with tumors in organs like the liver or pancreas that cannot be removed by surgery. The treatment uses short electrical pulses to help chemotherapy drugs enter cancer cells more effectively. The goal is to shrink …
Phase: NA • Sponsor: Istituto Oncologico Veneto IRCCS • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug HCB301 enters early human trials for tough cancers
Disease control Recruiting nowThis early-phase trial is testing a new drug called HCB301 in 50 adults with advanced solid tumors or Hodgkin lymphoma that has come back or not responded to other treatments. The main goals are to check the drug's safety, find the right dose, and see if it shows any signs of shr…
Phase: PHASE1 • Sponsor: FBD Biologics Limited • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New hope for deadly lymphoma combo: drug cocktail targets both cancer and immune chaos
Disease control Recruiting nowThis trial tests a new combination of drugs (MEPL-G) for people with a rare and aggressive lymphoma (NK/T-cell) that has triggered a life-threatening immune overreaction called HLH. The goal is to control both the cancer and the dangerous inflammation quickly. About 25 adults wil…
Phase: PHASE1, PHASE2 • Sponsor: Beijing Tongren Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Double-Team attack: new CAR-T therapy targets two cancer markers to outsmart relapse
Disease control Recruiting nowThis study tests a new type of CAR-T cell therapy that targets two different markers on cancer cells at once, aiming to prevent the cancer from escaping treatment. It is for adults with several types of blood cancers that have come back or not responded to standard treatments. Pa…
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New hope for hard-to-treat nose and throat cancer: targeted drug combo shows promise
Disease control Recruiting nowThis study tests a drug called becotatug vedotin in people with advanced nasopharyngeal cancer whose tumors didn't shrink enough after standard chemo-immunotherapy. About 59 adults will receive the drug during and after radiation therapy. The goal is to see if this approach can p…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Could a $4 heart pill beat a cancer? new trial tests propranolol for kaposi sarcoma
Disease control Recruiting nowThis phase II trial tests whether propranolol, a cheap and widely available blood pressure medicine, can shrink Kaposi sarcoma tumors in adults. The study enrolls 25 people with measurable lesions, including those with HIV. Researchers hope for a 45% response rate with fewer side…
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New pill shows early promise against tough cancers
Disease control Recruiting nowThis early-stage study is testing a new oral drug called CS23546 in about 156 adults with advanced solid tumors or lymphoma that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. Resear…
Phase: PHASE1 • Sponsor: Chipscreen Biosciences, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Experimental virus therapy takes on advanced cancers in first human trial
Disease control Recruiting nowThis early-stage trial is testing a new treatment called VET3-TGI, a virus designed to infect and destroy cancer cells. It is being given alone or with the immunotherapy drug atezolizumab to 60 people with advanced solid tumors that have not responded to standard treatments. The …
Phase: PHASE1 • Sponsor: KaliVir Immunotherapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Immune cell army targets Hard-to-Treat throat cancer
Disease control Recruiting nowThis early-phase study tests whether specially engineered immune cells (CAR-T and TCR-T) can safely fight Epstein-Barr virus (EBV)-positive nasopharyngeal carcinoma that has returned or not responded to treatment. About 24 adults will receive one of two types of cell therapy, wit…
Phase: EARLY_PHASE1 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Supercharged T-Cells take on stubborn lymphomas
Disease control Recruiting nowThis early-stage trial is testing a new type of immunotherapy for people with CD30-positive blood cancers that have come back or not responded to treatment. The therapy uses a patient's own immune cells, which are collected, modified with a special antibody, and then given back t…
Phase: PHASE1 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Engineered immune cells take on tough blood cancers in new trial
Disease control Recruiting nowThis study tests a personalized cell therapy called Talikabtagene Autoleucel for people with B-cell leukemia or lymphoma that has returned or not responded to standard treatment. The therapy uses a patient's own immune cells, which are modified in a lab to recognize and attack ca…
Phase: PHASE2, PHASE3 • Sponsor: Health Institutes of Turkey • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New chemo formula could cut side effects in lymphoma transplants
Disease control Recruiting nowThis phase 2 trial is testing a new formulation of the chemotherapy drug carmustine that doesn't contain ethanol, compared to the standard version that does. Both are used as part of the BEAM conditioning regimen before an autologous stem cell transplant in adults with Hodgkin or…
Phase: PHASE2 • Sponsor: VIVUS LLC • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Blood test may allow safer, Lower-Dose radiation for throat cancer patients
Disease control Recruiting nowThis study tests whether a blood test that detects HPV DNA can guide doctors to safely use a lower dose of radiation for people with HPV-related throat cancer. About 45 adults with early-stage HPV-positive oropharyngeal cancer will receive radiation and chemotherapy. The goal is …
Phase: PHASE2 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Could less radiation be enough for HPV throat cancer?
Disease control Recruiting nowThis study is for people with HPV-positive oropharyngeal (throat) cancer who have had surgery. Researchers want to see if giving a lower dose of radiation to a smaller area (just the neck, not the original tumor site) works as well as the standard higher dose. The goal is to redu…
Phase: NA • Sponsor: Georgetown University • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New hope for kids: drug may shield against dangerous viruses after transplant
Disease control Recruiting nowThis study tests whether the drug letermovir can prevent serious viral infections in children with EBV-related blood disorders who receive a stem cell transplant. About 80 children will be enrolled, and researchers will monitor for infections and other transplant complications. T…
Phase: NA • Sponsor: Beijing Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug takes aim at Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-stage trial tests a new oral drug called NX-2127 in adults with advanced B-cell cancers (like certain leukemias and lymphomas) that have not responded to standard treatments. The drug works by breaking down a protein that helps cancer cells grow. The main goals are to …
Phase: PHASE1 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New combo therapy aims to tame rare lymphoma without heavy side effects
Disease control Recruiting nowThis study is for people with early-stage nasal-type NK/T-cell lymphoma who have not had treatment before. It tests a personalized approach using a PD-1 antibody (a type of immunotherapy) combined with radiation therapy. The goal is to improve disease control while reducing side …
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Immunotherapy combo trial aims to boost survival in head and neck cancer
Disease control Recruiting nowThis phase II trial is testing whether adding the immunotherapy drug Toripalimab to different platinum-based chemotherapy regimens, followed by standard chemoradiotherapy, can improve outcomes for people with locally advanced nasopharyngeal cancer. About 243 participants will be …
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New hope for young hodgkin patients: drug combo aims to cut radiation
Disease control Recruiting nowThis study is testing a drug called brentuximab vedotin, combined with chemotherapy, for children, adolescents, and young adults newly diagnosed with classical Hodgkin lymphoma. The goal is to see if this approach can achieve a faster and more complete response, allowing fewer pa…
Phase: PHASE2, PHASE3 • Sponsor: Children's Cancer Group, China • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New combo therapy aims to improve survival in advanced nose cancer
Disease control Recruiting nowThis phase 3 trial tests whether a new drug (Becotatug vedotin) plus immunotherapy (sintilimab) and standard chemoradiation works better than current standard treatment for high-risk nasopharyngeal cancer. About 266 adults with advanced but non-spread cancer will be randomly assi…
Phase: PHASE3 • Sponsor: First Affiliated Hospital of Guangxi Medical University • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Could less radiation be just as effective for HPV throat cancer?
Disease control Recruiting nowThis study is for people with HPV-related throat cancer who have had surgery. It tests whether a lower, personalized dose of radiation (and sometimes chemo) can control the cancer while causing fewer side effects and improving quality of life. About 111 adults whose cancer was re…
Phase: NA • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Proton beam takes aim at returning throat cancer
Disease control Recruiting nowThis study is testing a precise type of radiation called proton therapy for people whose nasopharyngeal cancer has come back. The goal is to see if it can control the cancer while causing fewer severe side effects than standard treatments. About 52 adults with recurrent, non-spre…
Phase: NA • Sponsor: Guangzhou Concord Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Donor immune cells take on tough leukemia in early trial
Disease control Recruiting nowThis early-phase trial tests a two-step approach for people with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. First, patients receive donor-derived CD19 CAR T cells, then a stem cell transplant from the same donor, followed by donor-derive…
Phase: PHASE1 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Personalized vaccine takes on head and neck cancer in early trial
Disease control Recruiting nowThis early-phase trial tests a personalized vaccine made from a patient's own tumor cells, given alone or with the immunotherapy drug pembrolizumab, for people with head and neck cancer that has returned or spread. The main goals are to check safety, find the best dose, and see i…
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New cell therapy targets EBV-Linked cancers in early trial
Disease control Recruiting nowThis early-phase study is testing an experimental cell therapy called EBV-AST for people with Epstein-Barr virus (EBV)-related lymphoproliferative disorders, including certain blood cancers and post-transplant complications. About 18 adults will receive up to 3 infusions of the t…
Phase: PHASE1, PHASE2 • Sponsor: Daihong Liu • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New combo aims to boost CAR T-Cell therapy for rare lymphoma
Disease control Recruiting nowThis phase 2 trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard CAR T-cell therapy can improve outcomes for people with relapsed or refractory primary mediastinal B-cell lymphoma. About 35 participants will receive pembrolizumab before and afte…
Phase: PHASE2 • Sponsor: Jennifer Crombie, MD • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Could less radiation be just as good for some throat cancers?
Disease control Recruiting nowThis phase 3 trial is testing whether a lower dose of radiation, combined with chemotherapy and an immunotherapy drug called Camrelizumab, can control stage III nasopharyngeal cancer as well as the standard higher dose. About 593 patients whose tumors respond well to initial trea…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Engineered immune cells take on childhood blood cancers in early trial
Disease control Recruiting nowThis early-phase trial is testing a new CAR T-cell therapy called AUTO1 (obe-cel) in up to 30 children with B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. The therapy uses the child's own immune cells, which are…
Phase: PHASE1 • Sponsor: Autolus Limited • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Experimental therapy offers hope for kids with Tough-to-Treat leukemia
Disease control Recruiting nowThis early-stage trial tests a new type of CAR T-cell therapy (CMD63) in 16 children whose B-cell acute lymphoblastic leukemia has returned or not responded to standard treatments. The therapy uses specially engineered immune cells to target and kill cancer cells. The main goal i…
Phase: PHASE1 • Sponsor: Chulalongkorn University • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New drug combo aims to tackle recurrent brain lymphomas
Disease control Recruiting nowThis phase 2 trial is testing whether a combination of two drugs, zanubrutinib and pemetrexed, can safely control or shrink brain lymphomas that have come back or not responded to treatment. About 15 participants will receive the drugs in cycles, followed by maintenance therapy w…
Phase: PHASE2 • Sponsor: Baptist Health South Florida • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Less radiation, same control? new trial aims to boost quality of life for throat cancer patients
Disease control Recruiting nowThis study tests whether a shorter, lower-dose course of radiation after robotic surgery can improve quality of life for people with HPV-related throat cancer. About 42 adults who have had robotic surgery will receive a reduced radiation schedule. The goal is to see if this appro…
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New CAR-T therapy SYNCAR-100 enters early human testing for tough leukemia
Disease control Recruiting nowThis early-phase study tests SYNCAR-100, a type of cell therapy (CAR-T), in 16 adults with CD19-positive B-cell acute lymphoblastic leukemia that has come back or not responded to standard treatment. Participants receive four weekly injections, then are followed for safety and tu…
Phase: EARLY_PHASE1 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Double-Target CAR-T therapy takes on tough blood cancers
Disease control Recruiting nowThis phase 1/2 trial is testing a new type of CAR-T cell therapy that targets two proteins (CD19 and CD20) on cancer cells, aiming to improve treatment for people with relapsed or refractory B-cell cancers like lymphoma and leukemia. The study will enroll up to 100 adults and eva…
Phase: PHASE1, PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New combo therapy aims to boost remission in hodgkin lymphoma
Disease control Recruiting nowThis phase 4 study is testing the safety and effectiveness of brentuximab vedotin (Adcetris) combined with standard chemotherapy (doxorubicin, vinblastine, and dacarbazine) in 124 Indian adults with untreated stage 3 or 4 classical Hodgkin lymphoma. Participants will receive the …
Phase: PHASE4 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New hope for rare sarcoma patients: AL3818 drug trial underway
Disease control Recruiting nowThis phase 3 trial tests the drug AL3818 (anlotinib) in people with advanced alveolar soft part sarcoma, leiomyosarcoma, or synovial sarcoma. Currently, only patients with alveolar soft part sarcoma are being enrolled. Participants receive AL3818 pills or a standard chemotherapy …
Phase: PHASE3 • Sponsor: Advenchen Laboratories, LLC • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Can immune booster cells revive failing CAR-T therapy in leukemia?
Disease control Recruiting nowThis study tests whether adding cytokine-induced killer (CIK) cells can prevent CAR-T cells from wearing out too early in children and young adults with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia. About 213 participants will be randomly assigned to receive eith…
Phase: NA • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Could keytruda before surgery keep merkel cell cancer away?
Disease control Recruiting nowThis phase 2 trial is testing whether the immunotherapy drug pembrolizumab (Keytruda) can shrink Merkel cell carcinoma before surgery and lower the risk of it returning afterward. About 15 people with stage I to III Merkel cell carcinoma that can be surgically removed will receiv…
Phase: PHASE2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New cocktail of drugs shows promise for Tough-to-Treat throat cancer
Disease control Recruiting nowThis phase II trial is testing whether adding an immunotherapy drug (envafolimab) and a blood-vessel blocker (endostatin) to standard chemoradiotherapy can improve outcomes for 30 people with locally advanced nasopharyngeal carcinoma. The main goal is to see how many patients hav…
Phase: PHASE2 • Sponsor: Chongqing University Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Can a cancer pill keep bone sarcomas at bay?
Disease control Recruiting nowThis study tests whether the drug regorafenib can help prevent bone sarcomas from coming back after initial treatment. About 168 people aged 12 and older with various bone sarcomas will be randomly assigned to take regorafenib for up to 12 months or to receive standard monitoring…
Phase: NA • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New drug cocktail IoVeX offers hope for relapsed leukemia patients
Disease control Recruiting nowThis early-phase trial tests whether a combination of three drugs—inotuzumab ozogamicin, venetoclax, and dexamethasone (IoVeX)—is safe for children and adults with relapsed B-cell acute lymphoblastic leukemia (B-ALL). About 28 participants will receive the drugs over one or two 2…
Phase: PHASE1 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New hope for brain cancer: Triple-Drug attack shows promise
Disease control Recruiting nowThis study tests a combination of three drugs (thiotepa, pirtobrutinib, and sintilimab) for people with a type of brain lymphoma that has come back or is hard to treat. The goal is to see if this mix can shrink tumors and help patients live longer. About 24 adults will take part,…
Phase: PHASE2 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New hope for bone sarcoma: regorafenib maintenance trial launches
Disease control Recruiting nowThis phase 2 trial tests whether the drug regorafenib can help keep high-grade bone sarcomas from growing in patients who still have some disease after standard treatment. About 36 people aged 12 and older will take regorafenib daily for up to 12 months. The main goal is to see h…
Phase: PHASE2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Can a common cholesterol drug boost immunotherapy against head and neck cancer?
Disease control Recruiting nowThis phase II trial tests whether adding lovastatin, a common cholesterol-lowering drug, to the immunotherapy pembrolizumab can help shrink tumors in people with head and neck cancer that has returned or spread. The study will enroll 28 adults whose tumors express PD-L1. Research…
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Promising cocktail targets brain cancer
Disease control Recruiting nowThis phase 2 trial is testing a combination of four drugs (PD-1 inhibitor, rituximab, methotrexate, and orelabrutinib) in 50 people with newly diagnosed or relapsed central nervous system lymphoma. The goal is to see if this mix can stop the cancer from growing for at least a yea…
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New hope for rare blood cancer: platform trial tests multiple drugs at once
Disease control Recruiting nowThis study is testing three oral drugs—roginolisib, golcadomide, and azacitidine—alone or in combination for people with peripheral T-cell lymphoma that has come back or not responded to treatment. The trial has two phases: Phase 1 finds safe doses, and Phase 2 checks if the drug…
Phase: PHASE1, PHASE2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New combo aims to tackle tough lymphomas
Disease control Recruiting nowThis phase II trial tests a combination of two drugs—pembrolizumab (an immunotherapy) and ATRA (a vitamin A derivative)—in 24 adults with relapsed or refractory Hodgkin lymphoma or B-Non-Hodgkin lymphoma. The goal is to see if the combo is safe and can shrink tumors. Participants…
Phase: PHASE2 • Sponsor: Rita Assi • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Off-the-Shelf immune cells take on Hard-to-Treat lymphomas
Disease control Recruiting nowThis early-phase trial is testing a combination of donor natural killer (NK) cells and the drug mogamulizumab in 12 patients with relapsed or refractory cutaneous T-cell lymphoma or adult T-cell leukemia/lymphoma. The NK cells are grown in the lab and given 'off the shelf' to boo…
Phase: PHASE1 • Sponsor: John Reneau • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New drug YK012 tested in early leukemia trial
Disease control Recruiting nowThis early-stage trial is testing a new drug called YK012 in 46 people with B-cell acute lymphoblastic leukemia (B-ALL). The main goals are to check the drug's safety, find the right dose, and see if it shows any signs of fighting the cancer. Participants will receive YK012 throu…
Phase: PHASE1, PHASE2 • Sponsor: Excyte Biopharma Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Tailored transplant doses aim to beat blood cancer
Disease control Recruiting nowThis phase 2 trial tests a personalized approach to stem cell transplants for people with blood cancers like leukemia and lymphoma. Instead of a one-size-fits-all chemotherapy and radiation regimen, doctors adjust the doses based on each patient's risk. The goal is to improve the…
Phase: PHASE2 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Off-the-Shelf CAR t cells take on tough lymphomas and leukemias
Disease control Recruiting nowThis early-phase trial is testing a new type of CAR T cell therapy called Azer-cel, which is made from healthy donor cells rather than the patient's own cells. It aims to treat adults with relapsed or refractory non-Hodgkin lymphoma, B-cell acute lymphoblastic leukemia, and relat…
Phase: PHASE1 • Sponsor: Imugene Limited • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Cord blood transplant offers new hope for rare EBV diseases
Disease control Recruiting nowThis study tests whether a transplant of donated umbilical cord blood can help people aged 14 to 80 with serious diseases caused by the Epstein-Barr virus (EBV), such as certain lymphomas or chronic active EBV infection. The goal is to control the disease and improve survival, bu…
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New hope for hodgkin lymphoma: drug combo aims to boost transplant success
Disease control Recruiting nowThis phase 2 trial tests whether combining two drugs, pembrolizumab and brentuximab vedotin, can better shrink or eliminate Hodgkin lymphoma compared to standard chemotherapy (GDP) before a stem cell transplant. About 84 adults with relapsed or refractory classical Hodgkin lympho…
Phase: PHASE2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Second radiation may boost survival in returning throat cancer
Disease control Recruiting nowThis study is for people whose nasopharyngeal cancer has come back after initial treatment and cannot be removed by surgery. Participants first receive a combination of chemotherapy and an immunotherapy drug (PD-1 inhibitor). Those whose tumors shrink or disappear are then random…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New combo aims to boost transplant success in Hodgkin's lymphoma
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy (BEGEV) helps people with Hodgkin's lymphoma that has returned or not responded to first treatment. About 122 adults aged 18-60 will receive the combination before a stem cell transplant.…
Phase: PHASE1, PHASE2 • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug duo takes on stubborn Epstein-Barr virus
Disease control Recruiting nowThis study tests whether combining two drugs, golidocitinib and selinexor, can control chronic active Epstein-Barr virus disease (CAEBVD). Researchers will enroll 28 adults with CAEBVD and track how well the treatment reduces symptoms and lowers virus levels in the blood. It is a…
Phase: PHASE2, PHASE3 • Sponsor: Beijing Friendship Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Smart scans and DNA tests guide lymphoma treatment
Disease control Recruiting nowThis study tests a new way to treat a rare type of nasal lymphoma (NK/T cell lymphoma) by using PET scans and blood tests for the Epstein-Barr virus to decide the best treatment plan. About 89 newly diagnosed patients will receive a combination of chemotherapy, radiation, and imm…
Phase: NA • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Could less be more? Radiation-Only trial for nasopharyngeal cancer
Disease control Recruiting nowThis study looks at whether using only targeted radiation (IMRT) can effectively control stage IB nasopharyngeal cancer in patients without high-risk features. About 169 adults aged 18-70 with newly diagnosed, early-stage disease will be followed to see how many remain cancer-fre…
Sponsor: Qiaojuan Guo • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Suicide-Gene t cells aim to stop blood cancer relapse
Disease control Recruiting nowThis early-phase trial tests whether infusing specially designed immune cells can prevent blood cancer from coming back after a stem cell transplant. The cells target a specific protein (HLA-DPB1*04:01) found on many cancer cells and include a 'suicide switch' to turn them off if…
Phase: PHASE1 • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:15 UTC
-
New immune combo targets hard-to-treat nose and throat cancer
Disease control Recruiting nowThis study tests a combination of two immune-boosting drugs (iparomlimab and tuvonralimab) plus a targeted antibody (nimotuzumab) in people with advanced nasopharyngeal cancer that got worse after standard first treatment. About 41 adults aged 18-70 will receive the therapy to se…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Experimental combo aims to reboot immune system against Hard-to-Treat cancers
Disease control Recruiting nowThis study is testing an anti-PD-1 antibody (a type of immunotherapy) alone or combined with low-dose decitabine and/or standard chemotherapy in people whose cancers have come back or not responded to treatment. The trial includes patients with several cancer types, such as lymph…
Phase: PHASE1, PHASE2 • Sponsor: Han weidong • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New smart drug TQB6411 targets two cancer proteins in early human trial
Disease control Recruiting nowThis Phase 1 trial tests TQB6411, an antibody-drug conjugate designed to bind to EGFR and c-Met proteins on tumor cells, blocking their growth signals and releasing a toxin to kill the cells. The study will enroll 216 adults with advanced malignant tumors to find the safest dose …
Phase: PHASE1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New drug cocktail aims to outdo chemo for tough throat cancer
Disease control Recruiting nowThis Phase 3 trial tests whether combining two drugs, MRG003 and pucotenlimab, works better than standard chemotherapy for people with nasopharyngeal cancer that has returned or spread. About 446 participants will be randomly assigned to receive either the new combo or one of thr…
Phase: PHASE3 • Sponsor: Shanghai Miracogen Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Proton beam vs. standard radiation: which is safer for advanced throat cancer?
Disease control Recruiting nowThis study compares two radiation methods—proton therapy and standard photon therapy—for people with advanced nasopharyngeal cancer. All 300 participants will receive chemotherapy and immunotherapy alongside radiation. The goal is to see which approach causes fewer severe side ef…
Phase: PHASE3 • Sponsor: Man Hu • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New pill aims to fight advanced lymphoma when other treatments fail
Disease control Recruiting nowThis early-stage trial tests an oral drug called AUR112 in 40 adults with relapsed advanced lymphoma. The main goals are to check safety, find the right dose, and see how the drug moves through the body. It is the first time this drug is being tested in humans.
Phase: PHASE1 • Sponsor: Aurigene Discovery Technologies Limited • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New mRNA CAR-T therapy aims to tackle tough blood cancers
Disease control Recruiting nowThis study tests a new type of CAR-T cell therapy that uses mRNA to target two proteins (CD19 and CD20) on cancer cells. It is for people with B-cell lymphoma or leukemia that has come back or not responded to treatment. The goal is to see if it is safe and effective, with up to …
Phase: PHASE2 • Sponsor: Daihong Liu • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New hope for recurrent throat cancer: Radiation-Immunotherapy combo shows promise
Disease control Recruiting nowThis phase II trial tests a new approach for recurrent nasopharyngeal carcinoma (a type of throat cancer) that has come back after initial treatment and cannot be removed by surgery. The treatment combines a special radiation schedule (low and high doses) with an immunotherapy dr…
Phase: PHASE2 • Sponsor: Jiangxi Provincial Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New blood test may sharpen diagnosis of autoimmune liver disease
Diagnosis Recruiting nowThis study evaluates whether a blood test measuring polyreactive immunoglobulin G (pIgG) can more accurately diagnose autoimmune hepatitis (AIH) and distinguish it from other liver conditions. Researchers will collect blood samples from 400 adults undergoing liver biopsy for susp…
Sponsor: Hannover Medical School • Aim: Diagnosis
Last updated Jul 17, 2026 00:00 UTC
-
Could a special MRI spot brain lymphoma without a biopsy?
Diagnosis Recruiting nowThis trial investigates whether a special MRI technique using hyperpolarized carbon-13 pyruvate can safely and effectively detect primary central nervous system lymphoma, a rare type of brain cancer. Participants receive an injection of the substance before an MRI scan, and resea…
Phase: PHASE1 • Sponsor: James Rubenstein • Aim: Diagnosis
Last updated Jul 16, 2026 00:00 UTC
-
New PET scan targets hidden cancers with precision
Diagnosis Recruiting nowThis study tests a special PET/CT scan that uses radioactive tracers to find cancers that have a protein called CD70 on their surface. The cancers being studied include kidney cancer, lymphoma, and nasopharyngeal cancer. About 300 adults will receive an injection of the tracer an…
Phase: PHASE2 • Sponsor: RenJi Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:31 UTC
-
Breathing without blowing: new scanner may diagnose lung disease in seconds
Diagnosis Recruiting nowThis study tests a non-invasive imaging method called electrical impedance tomography (EIT) to monitor lung function in 400 adults with lung diseases like COPD, asthma, or pneumonia. Unlike standard spirometry, which requires active blowing, EIT works even in patients who cannot …
Sponsor: University Hospital Olomouc • Aim: Diagnosis
Last updated Jun 27, 2026 09:00 UTC
-
New scan could sharpen cancer detection
Diagnosis Recruiting nowThis early-stage study is testing a new imaging agent called 68Ga-FL-031 to see if it can better detect and stage certain cancers, including small cell lung, breast, and nasopharyngeal tumors. Ten adults with suspected or confirmed cancer will receive both the new PET scan and a …
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Diagnosis
Last updated Jun 27, 2026 08:06 UTC
-
New vaccine aims to shield stem cell patients from dangerous virus
Prevention Recruiting nowThis early-phase trial tests a vaccine (CMV-MVA Triplex) given to both stem cell donors and recipients to boost immunity against cytomegalovirus (CMV) and prevent active infection after a half-matched stem cell transplant. About 46 people with various blood cancers will take part…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Prevention
Last updated Jul 30, 2026 00:00 UTC
-
Shingles breakthrough? calcitonin shots aim to stop chronic pain before it starts
Prevention Recruiting nowThis phase 3 trial tests whether adding daily calcitonin injections to standard shingles treatment can prevent postherpetic neuralgia, a painful nerve condition that can last for months or years. Researchers will enroll 168 adults aged 50 and older who have had a shingles rash fo…
Phase: PHASE3 • Sponsor: Tanta University • Aim: Prevention
Last updated Jul 08, 2026 00:00 UTC
-
Could a probiotic cream shield cancer patients from radiation burns?
Prevention Recruiting nowThis early-stage trial tests a cream made from inactivated Akkermansia muciniphila bacteria to prevent skin injury in 40 breast or head/neck cancer patients receiving radiation. The cream is applied three times daily to the radiation area. The main goal is to see if it is safe an…
Phase: PHASE1 • Sponsor: West China Hospital • Aim: Prevention
Last updated Jun 27, 2026 13:04 UTC
-
Poop pills to prevent transplant rejection? new trial tests fecal transplants in blood cancer patients
Prevention Recruiting nowThis study tests whether a fecal microbiota transplant (FMT) can prevent graft-versus-host disease (GvHD) in 150 adults with blood cancers who receive a stem cell transplant. Patients get a single FMT enema within four weeks of transplant. The main goal is to see if FMT improves …
Phase: PHASE2 • Sponsor: University Hospital, Clermont-Ferrand • Aim: Prevention
Last updated Jun 27, 2026 13:04 UTC
-
Shingles vaccine protection tested over 6 years in 24,740 adults
Prevention Recruiting nowThis study looks at how well a live shingles vaccine prevents shingles over 6 years in adults aged 40 and older. It follows about 24,740 people who were in an earlier vaccine trial, comparing those who got the vaccine first to those who got it later. Researchers will track new sh…
Sponsor: Jiangsu Province Centers for Disease Control and Prevention • Aim: Prevention
Last updated Jun 27, 2026 12:33 UTC
-
Shingles shot may shield brain: 33,000 seniors test dementia link
Prevention Recruiting nowThis study is testing whether the Shingrix vaccine, already used to prevent shingles, can also lower the risk of dementia in adults aged 76 and older. Over 33,000 participants in Finland will receive either the vaccine or a placebo. Researchers will track new dementia diagnoses o…
Phase: PHASE4 • Sponsor: GlaxoSmithKline • Aim: Prevention
Last updated Jun 27, 2026 12:32 UTC
-
Shingles shot may shield seniors from heart attacks and dementia
Prevention Recruiting nowThis large study in Denmark is testing whether the shingles vaccine (Shingrix) can do more than prevent shingles—it may also lower the risk of heart attacks, strokes, and dementia. About 162,000 adults aged 65 and older will either get the vaccine or no vaccine, and researchers w…
Phase: PHASE4 • Sponsor: Tor Biering-Sørensen • Aim: Prevention
Last updated Jun 27, 2026 12:29 UTC
-
Can a common antiseptic spray stop radiation burns in cancer patients?
Prevention Recruiting nowThis study tests whether a chlorhexidine spray can prevent severe skin reactions caused by radiation therapy in people with nasopharyngeal cancer. About 148 participants will use the spray or a placebo during their treatment. The goal is to see if the spray reduces the chance of …
Phase: PHASE3 • Sponsor: Jiangxi Provincial Cancer Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:26 UTC
-
Common pain gel could shield cancer patients from radiation burns
Prevention Recruiting nowThis study tests whether a gel containing diclofenac, a common anti-inflammatory drug, can prevent severe skin irritation caused by radiation therapy. About 156 adults with head/neck or breast cancer will apply the gel or a placebo to the treated skin three times daily during the…
Phase: NA • Sponsor: The Second Affiliated Hospital of Hainan Medical University • Aim: Prevention
Last updated Jun 27, 2026 12:03 UTC
-
Shingles sufferers: could this pill stop your pain from becoming chronic?
Prevention Recruiting nowThis study tests whether the oral medication venlafaxine, typically used for depression, can prevent postherpetic neuralgia—a persistent nerve pain that often follows a shingles rash. Researchers will enroll 832 adults who have had a shingles rash for less than 30 days and are ex…
Phase: NA • Sponsor: Beijing Tiantan Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:01 UTC
-
Cockroach extract may shield cancer patients from radiation burns
Prevention Recruiting nowThis study tests a liquid made from cockroach extract (Meilian Fuxin) to prevent severe skin damage in head and neck cancer patients receiving radiation therapy. About 60 participants will apply the solution to their skin during treatment. The goal is to see if it reduces the ris…
Phase: PHASE2, PHASE3 • Sponsor: West China Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:00 UTC
-
Donor vaccine aims to shield transplant patients from common virus
Prevention Recruiting nowThis phase 2 trial tests a vaccine called CMV-MVA Triplex, given to stem cell donors before they donate. The goal is to boost the donor's immunity against cytomegalovirus (CMV), which can then be passed to the transplant patient. Researchers hope this will prevent CMV infection i…
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Prevention
Last updated Jun 27, 2026 11:00 UTC
-
Can a cancer drug stop leukemia before it starts?
Prevention Recruiting nowThis study tests whether the drug mogamulizumab can prevent adult T-cell leukemia/lymphoma (ATL) in people infected with HTLV-1 who are at high risk. About 134 participants will receive low doses of the drug over several weeks. The goal is to see if it can reduce the virus levels…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Prevention
Last updated Jun 27, 2026 09:11 UTC
-
New drug aims to ease painful mouth sores for head and neck cancer patients
Symptom relief Recruiting nowThis phase II trial tests whether adding BMX-001 to standard symptom management can reduce severe mouth sores in head and neck cancer patients receiving chemoradiation. About 98 participants will receive either BMX-001 or a placebo alongside usual care. The goal is to see if BMX-…
Phase: PHASE2 • Sponsor: NRG Oncology • Aim: Symptom relief
Last updated Aug 18, 2026 04:00 UTC
-
Can computer games clear the fog? new study tests brain training for ME/CFS
Symptom relief Recruiting nowThis study compares two brain-training programs for adults with ME/CFS who experience brain fog. Both programs include computer games and a mild nerve stimulation device, but one focuses on processing speed and daily tasks while the other emphasizes relaxation and healthy habits.…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC
-
Taurine trial targets long COVID brain fog
Symptom relief Recruiting nowThis study tests whether taking taurine supplements can reduce brain fog, memory problems, and fatigue in people with Long COVID. About 300 adults who had COVID-19 at least 3 months ago will take taurine or a placebo for 3 months. Researchers will measure changes in fatigue and t…
Phase: PHASE2, PHASE3 • Sponsor: University of Alberta • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
Can a new pill quiet the lingering fire of shingles nerve pain?
Symptom relief Recruiting nowThis trial tests whether an experimental tablet called HL-1186 can reduce the persistent nerve pain that sometimes lingers after a shingles rash heals, a condition known as postherpetic neuralgia. About 200 adults with this pain will receive either HL-1186, a placebo, or the stan…
Phase: PHASE2 • Sponsor: Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
Micro-Choices, macro impact? a novel behavioral approach takes on fatigue
Symptom relief Recruiting nowThis trial tests whether a program built around small, deliberate choices — called micro-choices — can help people with persistent fatigue, including those with long COVID. Participants attend a four-day group workshop and receive three weeks of digital support to build new habit…
Phase: NA • Sponsor: University Hospital, Basel, Switzerland • Aim: Symptom relief
Last updated Aug 08, 2026 00:03 UTC
-
Can a precise nerve block stop shingles pain before it becomes chronic?
Symptom relief Recruiting nowThis trial compares two ultrasound-guided nerve blocks — the midpoint transverse process to pleura (MTP) block and the erector spinae plane (ESP) block — for treating acute pain from shingles (herpes zoster) on the chest. About 90 adults with moderate to severe pain will receive …
Phase: NA • Sponsor: Tanta University • Aim: Symptom relief
Last updated Jul 31, 2026 00:00 UTC
-
Could a Once-Daily pill ease nerve pain just as well as the standard Twice-Daily dose?
Symptom relief Recruiting nowThis phase 3 trial tests whether an extended-release (once-daily) form of pregabalin works as well as the standard immediate-release (twice-daily) form for relieving nerve pain caused by diabetic peripheral neuropathy or postherpetic neuralgia. About 348 adults aged 18 to 75 with…
Phase: PHASE3 • Sponsor: Brainfarma Industria Química e Farmacêutica S/A • Aim: Symptom relief
Last updated Jul 22, 2026 00:00 UTC
-
Magnetic pulses may clear long COVID brain fog
Symptom relief Recruiting nowThis trial tests whether a rapid, noninvasive magnetic brain stimulation called iTBS can reduce symptoms like brain fog, depression, and anxiety in people with Long COVID. Participants receive either real or sham stimulation and complete surveys, cognitive tests, and brain scans.…
Phase: PHASE2 • Sponsor: University of New Mexico • Aim: Symptom relief
Last updated Jul 17, 2026 00:00 UTC
-
Could an ALS drug clear the fog of chemo brain?
Symptom relief Recruiting nowThis study tests whether riluzole, a drug already used for ALS, can help cancer survivors who struggle with memory, focus, and mental clarity after treatment — a condition called cancer-related cognitive impairment. Researchers will measure changes in a brain protein called BDNF …
Phase: PHASE2 • Sponsor: University of California, Irvine • Aim: Symptom relief
Last updated Jul 16, 2026 00:00 UTC
-
New lozenge aims to ease radiation mouth sores for hours
Symptom relief Recruiting nowThis phase 3 trial tests whether a lozenge called BupiZenge, which contains the long-acting painkiller bupivacaine, can relieve mouth pain from radiation therapy better than the standard lidocaine rinse. About 150 adults with head and neck cancer will be randomly assigned to one …
Phase: PHASE3 • Sponsor: OncoZenge AB • Aim: Symptom relief
Last updated Jul 15, 2026 00:00 UTC
-
Mouth spray could tame agonizing swallowing pain during cancer radiation
Symptom relief Recruiting nowThis clinical trial tests whether a doxepin solution spray can relieve severe breakthrough pain when swallowing, a common side effect of radiation therapy for nasopharyngeal carcinoma. About 178 patients will be randomly assigned to receive either the doxepin spray or a placebo s…
Phase: NA • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Anti-Inflammatory diet tested as long COVID fatigue fix for seniors
Symptom relief Recruiting nowThis study tests whether following a healthy US-style diet rich in anti-inflammatory foods can reduce fatigue and improve muscle and physical function in adults aged 50 and older with long COVID. Over 16 weeks, participants are randomly assigned to either receive personalized die…
Phase: NA • Sponsor: University of Maryland, Baltimore • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Water workouts may clear long COVID brain fog
Symptom relief Recruiting nowThis study tests whether a program of water-based exercise followed by memory training can help Veterans with long COVID symptoms like brain fog and fatigue. About 50 people will take part over 8 months. The goal is to see if the program is safe, doable, and helpful.
Phase: NA • Sponsor: VA Office of Research and Development • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Can acupuncture needles zap shingles pain away?
Symptom relief Recruiting nowThis study looks at whether electroacupuncture (a type of acupuncture with mild electric pulses) can help relieve pain from shingles and reduce the chance of long-term nerve pain. About 228 adults with shingles will be split into three groups: one gets electroacupuncture plus sta…
Phase: NA • Sponsor: Dexiong Han • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Could an antidepressant ease long COVID fatigue?
Symptom relief Recruiting nowThis study tests whether fluvoxamine, an antidepressant, can reduce severe fatigue and other symptoms in people with post-COVID. 160 adults aged 18-70 with long-lasting fatigue after COVID will receive either the drug or a placebo for 12 weeks. The goal is to see if it improves e…
Phase: PHASE3 • Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
Nerve block shot could ease Long-COVID brain fog and fatigue?
Symptom relief Recruiting nowThis study tests if a nerve block injection in the neck can reduce long-COVID symptoms like fatigue, brain fog, and heart palpitations. About 78 adults with post-COVID condition will get either the real block or a fake injection to see if it helps. The goal is to find a safe, eff…
Phase: PHASE4 • Sponsor: University Health Network, Toronto • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
Taurine supplement tested as cheap fix for long COVID dizziness
Symptom relief Recruiting nowThis study tests whether taking taurine—a natural amino acid—for 12 weeks can improve blood vessel function and reduce dizziness when standing up in people with Long COVID. Researchers will measure blood flow, heart rate, and brain blood flow in 30 participants before and after s…
Sponsor: York University • Aim: Symptom relief
Last updated Jun 27, 2026 13:03 UTC
-
Herbal drink may soothe radiation mouth pain in cancer patients
Symptom relief Recruiting nowThis phase 3 trial tests whether Houyanqing Oral Liquid, a Chinese herbal mix, can prevent or reduce severe mouth sores caused by radiation therapy in 386 nasopharyngeal cancer patients. Participants take the liquid four times daily during radiation, alongside standard care. The …
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC
-
Brain retraining trial aims to ease chronic fatigue and long COVID symptoms
Symptom relief Recruiting nowThis study is testing a mind-body program called DNRS for people with ME/CFS (chronic fatigue syndrome) who may also have Long COVID. The program uses brain retraining to help calm overactive nerves and improve symptoms like fatigue, pain, and mood. Researchers will track quality…
Phase: NA • Sponsor: University of Alberta • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC
-
Saline solution tested as brain fog fix for long COVID and POTS patients
Symptom relief Recruiting nowThis study looks at whether a large IV bag of saline (salt water) can improve thinking problems like brain fog in people with Long COVID or a condition called POTS. About 100 adults will receive either a full or tiny dose of saline to compare effects on reaction time and memory. …
Phase: NA • Sponsor: University of Calgary • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC
-
Burst of hope: new brain stimulation tackles stubborn pain
Symptom relief Recruiting nowThis study tests a new type of deep brain stimulation called 'Burst-DBS' for people with long-term facial pain or pain after a stroke. Twenty adults will have electrodes placed in the thalamus (a pain-related brain area) and try both standard and burst stimulation patterns. The g…
Phase: NA • Sponsor: Insel Gruppe AG, University Hospital Bern • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
Could a tiny ear zap boost exercise recovery in chronic fatigue?
Symptom relief Recruiting nowThis study tests whether a device that gently stimulates a nerve in the ear (transcutaneous vagus nerve stimulation) can help people with chronic fatigue from fibromyalgia or long COVID get more benefit from exercise. 60 adults who still feel very tired after a standard exercise …
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Saint Etienne • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
New shot trio battles shingles nerve pain: exosomes, PRP, or steroids?
Symptom relief Recruiting nowThis study tests three different injections—exosomes, platelet-rich plasma (PRP), and steroids—to see which best eases long-term nerve pain after shingles. 45 adults with pain lasting at least 3 months will get four treatments every two weeks. Researchers will measure pain, quali…
Phase: NA • Sponsor: Zagazig University • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
Can pressurized oxygen clear long COVID brain fog?
Symptom relief Recruiting nowThis study tests whether breathing pure oxygen in a pressurized chamber (hyperbaric oxygen therapy) can improve thinking, memory, and other symptoms in people with long COVID. About 91 adults who have had cognitive problems for at least 3 months after a COVID infection will be ra…
Phase: NA • Sponsor: Assaf-Harofeh Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
New study tests brain games and nerve zap to clear long COVID fog and get people back to work
Symptom relief Recruiting nowThis study compares two cognitive rehab programs for adults with long COVID who have mild to moderate brain fog. Both programs include computer games, in-lab training, and a mild nerve stimulation device worn on the ear. One group focuses on processing speed and work-related task…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
Rehab program shows promise for long COVID sufferers with chronic illness
Symptom relief Recruiting nowThis study tests whether an 8-week program of supervised physical and cognitive exercises can improve walking, thinking, strength, and quality of life in 374 adults with Long COVID and conditions like high blood pressure or diabetes. Participants are randomly assigned to either t…
Phase: NA • Sponsor: Fundación Cardioinfantil Instituto de Cardiología • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
At-home treatments may bring back smell for long COVID sufferers
Symptom relief Recruiting nowThis study tests two at-home treatments—smell training and a gentle nerve stimulation device—for people with long COVID who have lost or distorted their sense of smell. About 145 adults will do daily sessions at home and attend three clinic visits over 12 weeks. The goal is to se…
Phase: PHASE2, PHASE3 • Sponsor: Medical University of South Carolina • Aim: Symptom relief
Last updated Jun 27, 2026 12:03 UTC
-
New drug DAOIB hopes to clear long COVID brain fog
Symptom relief Recruiting nowThis study tests a drug called DAOIB in 40 people with Long COVID who have memory and thinking problems (brain fog). Everyone gets the drug for 24 weeks, and researchers check their thinking skills, mood, and quality of life every 8 weeks. The goal is to see if DAOIB can help imp…
Phase: PHASE2 • Sponsor: Chang Gung Memorial Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 11:03 UTC
-
Ear stimulation device offers hope for kids with lingering concussion or COVID symptoms
Symptom relief Recruiting nowThis study tests a small device that sends gentle electrical pulses to nerves in the ear to help children ages 11-18 with post-concussion syndrome or long COVID symptoms like pain, nausea, and balance problems. Participants must have had symptoms for at least 3 months. The goal i…
Phase: NA • Sponsor: Children's Hospital of Orange County • Aim: Symptom relief
Last updated Jun 27, 2026 11:03 UTC
-
Ear-Zap therapy offers hope for shingles pain sufferers
Symptom relief Recruiting nowThis study tests a non-invasive device that gently stimulates a nerve in the ear to see if it can reduce pain and improve daily life for people with post-herpetic neuralgia (long-term nerve pain after shingles). About 34 adults aged 35-65 with persistent pain will receive the sti…
Phase: NA • Sponsor: Mohamed Hosny Ismail Easa • Aim: Symptom relief
Last updated Jun 27, 2026 11:02 UTC
-
Oxygen chamber treatment tested for long COVID fatigue relief
Symptom relief Recruiting nowThis study is testing whether hyperbaric oxygen therapy (breathing pure oxygen in a pressurized chamber) can improve symptoms like fatigue and brain fog in people with post-COVID syndrome. About 40 adults with long COVID will receive the treatment. The main goal is to see if a la…
Phase: NA • Sponsor: Sunnybrook Health Sciences Centre • Aim: Symptom relief
Last updated Jun 27, 2026 11:02 UTC
-
Could HIV drugs be the key to beating long COVID?
Symptom relief Recruiting nowThis study tests whether two HIV antiviral drugs, Truvada and Selzentry, can reduce symptoms in adults with Long COVID. Researchers think hidden viral activity may cause ongoing symptoms. 90 participants will take one of the drugs or a placebo daily for 90 days, and their health …
Phase: PHASE2 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Symptom relief
Last updated Jun 27, 2026 11:01 UTC
-
Earthworm enzyme trial aims to ease long covid and chronic fatigue
Symptom relief Recruiting nowThis study tests a dietary supplement called lumbrokinase in 120 adults with Long Covid, post-treatment Lyme disease syndrome, or ME/CFS. Participants take the supplement daily for 6 weeks. The goal is to see if it improves overall health and quality of life, as measured by a sim…
Phase: PHASE1, PHASE2 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Numbing cream may ease sting of cancer mapping shots
Symptom relief Recruiting nowThis study tests whether EMLA numbing cream can reduce pain from Technetium 99 injections used in lymphoscintigraphy, a standard mapping procedure for skin cancers like melanoma. About 100 adults with skin cancer will receive either EMLA cream or a placebo before the injection. T…
Phase: PHASE2 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Can oxygen therapy clear long COVID brain fog?
Symptom relief Recruiting nowThis study tests if hyperbaric oxygen therapy (breathing pure oxygen in a pressurized chamber) can ease lingering symptoms like brain fog and fatigue in people with Long COVID. Researchers will enroll 120 adults who had COVID-19 at least 3 months ago. The goal is to see if this t…
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Symptom relief
Last updated Jun 27, 2026 09:08 UTC
-
Shingles pain relief showdown: nerve block vs radiofrequency
Symptom relief Recruiting nowThis study compares two treatments for long-lasting nerve pain after shingles (postherpetic neuralgia). Researchers will give 50 adults either a nerve block or a radiofrequency treatment and measure pain levels. The goal is to find which option works better for easing this stubbo…
Sponsor: Diskapi Teaching and Research Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 09:08 UTC
-
App-Based workouts show promise for long COVID recovery
Symptom relief Recruiting nowThis study tests whether a 12-week exercise program delivered through a smartphone app can improve physical function and heart health in people with long COVID. Sixty adults with ongoing fatigue or shortness of breath after a COVID-19 infection will be randomly assigned to either…
Phase: NA • Sponsor: University of Nove de Julho • Aim: Symptom relief
Last updated Jun 27, 2026 09:05 UTC
-
Mind over long COVID: new study tests behavioral relief
Symptom relief Recruiting nowThis study tests whether a mind-body intervention, including educational sessions and personalized support, can reduce long COVID symptoms like pain, fatigue, and dizziness. Researchers will compare it to usual care and another mind-body program in 180 adults. The goal is to see …
Phase: NA • Sponsor: Beth Israel Deaconess Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 09:05 UTC
-
Could a neck injection ease long COVID fatigue and brain fog?
Symptom relief Recruiting nowThis study tests whether a single injection near a nerve cluster in the neck (stellate ganglion block) can reduce long COVID symptoms like fatigue, brain fog, and trouble breathing. About 40 adults with persistent symptoms will receive either the active injection or a placebo. Re…
Phase: NA • Sponsor: Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec • Aim: Symptom relief
Last updated Jun 27, 2026 09:03 UTC
-
Can a traditional chinese medicine beat long COVID fatigue?
Symptom relief Recruiting nowThis study tests whether Shengmai liquid, a traditional Chinese herbal drink, can reduce fatigue in people with Long COVID. One hundred adults aged 18-75 will take either the liquid or a placebo daily for 8 weeks. Researchers will measure changes in fatigue, mood, and sleep quali…
Phase: PHASE4 • Sponsor: Beijing University of Chinese Medicine • Aim: Symptom relief
Last updated Jun 27, 2026 09:03 UTC
-
Zapping away shingles pain: new trial tests pulsed radiofrequency
Symptom relief Recruiting nowThis study tests whether a noninvasive procedure called transcutaneous pulsed radiofrequency can reduce chronic pain from postherpetic neuralgia, a complication of shingles. The procedure delivers electrical pulses through electrodes placed on the skin over the painful area. Rese…
Sponsor: Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization • Aim: Symptom relief
Last updated Jun 27, 2026 09:02 UTC
-
New patch could ease shingles pain without strong drugs
Symptom relief Recruiting nowThis study tests whether a loxoprofen patch can safely reduce pain from shingles (herpes zoster). Researchers will compare standard treatment alone to standard treatment plus the patch in 750 adults with moderate to severe pain. The goal is to see if the patch provides better pai…
Phase: NA • Sponsor: Beijing Tiantan Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
Diet and exercise may ease chemo side effects for lymphoma patients
Symptom relief Recruiting nowThis study tests whether a Mediterranean diet and home-based exercise program can help lymphoma patients complete chemotherapy and reduce treatment-related side effects. Researchers will enroll 140 adults with untreated Hodgkin or non-Hodgkin lymphoma who need at least 6 cycles o…
Phase: NA • Sponsor: University of Miami • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
Could a muscle relaxant ease shingles pain?
Symptom relief Recruiting nowThis study tests whether adding the muscle relaxant baclofen to standard shingles treatment can better reduce moderate to severe pain. Researchers will enroll 750 adults with shingles rash for less than 90 days. Participants will receive either baclofen plus usual care or usual c…
Phase: NA • Sponsor: Beijing Tiantan Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
Antidepressant could ease shingles pain
Symptom relief Recruiting nowThis study tests whether adding the antidepressant tulodesvenlafaxine to standard shingles treatment can better relieve pain. It includes 750 adults with moderate to severe shingles pain. The goal is to see if this drug reduces pain scores more than usual care alone.
Phase: NA • Sponsor: Beijing Tiantan Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
New patch could ease shingles pain without pills
Symptom relief Recruiting nowThis study tests whether a flurbiprofen patch can safely reduce pain in people with shingles (herpes zoster). About 750 adults with moderate to severe pain will either receive the patch plus standard treatments (antivirals, opioids) or standard treatments alone. The goal is to se…
Phase: NA • Sponsor: Beijing Tiantan Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
Antidepressant could be new weapon against shingles pain
Symptom relief Recruiting nowThis study tests whether the antidepressant desvenlafaxine can reduce pain from shingles (herpes zoster) better than standard treatments alone. Researchers will enroll 750 adults with moderate to severe pain and compare those taking desvenlafaxine plus usual care to those receivi…
Phase: NA • Sponsor: Beijing Tiantan Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
Lifestyle plan aims to boost Well-Being in lymphoma survivors
Symptom relief Recruiting nowThis study tests whether a personalized healthy lifestyle plan can improve quality of life for people who have survived certain types of lymphoma (Hodgkin and some large B-cell lymphomas). Participants must be between 18 and 50 years old and have been in remission for 3 to 10 yea…
Phase: NA • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Symptom relief
Last updated Jun 27, 2026 08:10 UTC
-
Can acupuncture ease long COVID? tiny study aims to find out
Symptom relief Recruiting nowThis pilot study will test whether acupuncture, with or without Chinese herbal medicine, is a practical and helpful treatment for long COVID. Ten adults with long COVID will receive 16 acupuncture sessions over 8 weeks; half will also take herbal supplements. The main goal is to …
Phase: NA • Sponsor: Southern California University of Health Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 08:03 UTC
-
Scientists hunt for genetic clues in Virus-Linked cancers
Knowledge-focused Recruiting nowThis study collects tissue and blood samples from adults with HIV, other immune disorders, or cancers thought to be caused by viruses. Researchers will compare genes in cancer tissue to normal tissue to find genetic changes that drive these cancers. The goal is to better understa…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 04:00 UTC
-
Massive liver study seeks 8,000 volunteers to unlock disease secrets
Knowledge-focused Recruiting nowThis study aims to learn more about liver diseases like hepatitis B, C, and D by observing up to 8,050 participants over time. Participants will have yearly check-ups, blood and urine tests, and liver ultrasounds. Some may be offered experimental treatments if they qualify. The g…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Aug 18, 2026 04:00 UTC
-
Scientists seek samples to build better Cancer-Killing drugs
Knowledge-focused Recruiting nowThis study collects blood, urine, bone marrow, and tumor samples from people with hairy cell leukemia and other blood cancers, as well as from healthy volunteers. Researchers will use these samples to study the diseases and develop new treatments called immunotoxins, which use an…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 04:00 UTC
-
Cancer samples sought to unlock treatment secrets
Knowledge-focused Recruiting nowThis study collects blood, bone marrow, and tumor samples from 500 adults with cancer or pre-cancerous conditions. Researchers will use these samples to learn more about how cancers behave and why some respond differently to treatments. Participants provide samples over time and …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 04:00 UTC
-
Can tracking thousands of patients unlock the secrets of rare EBV-driven blood cancers?
Knowledge-focused Recruiting nowThis study follows 1,500 people with Epstein-Barr virus-positive T/NK-cell lymphoproliferative diseases — rare conditions where the virus drives abnormal immune cell growth. Researchers will collect medical history, treatment details, and blood samples to see how the diseases beh…
Sponsor: Rong Tao • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Scientists hunt for hidden COVID remnants in long COVID patients
Knowledge-focused Recruiting nowThis study aims to find out whether people with long COVID still have inactive remnants of the SARS-CoV-2 virus in their bodies. Researchers will collect tissue samples from 12 adults who have recovered from COVID-19, some with long COVID symptoms and some without. The goal is to…
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Brain scans reveal hidden inflammation in long COVID patients
Knowledge-focused Recruiting nowThis study uses a special PET scan to look for inflammation in the brains of people with long COVID who have neurological symptoms like brain fog or headaches. Researchers will compare these scans with those from healthy volunteers to better understand how the virus may affect th…
Phase: EARLY_PHASE1 • Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
A simple blood test may reveal hidden infertility risk in young cancer survivors
Knowledge-focused Recruiting nowThis study investigates whether a blood marker called anti-Müllerian hormone (AMH) can predict future infertility in children and adolescents who have undergone cancer treatment. Many young patients recover normal menstrual cycles or puberty after chemotherapy, but their ovarian …
Sponsor: Erasme University Hospital • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Scientists seek skin samples to unlock disease secrets
Knowledge-focused Recruiting nowThis study collects biological samples—like blood, skin biopsies, and swabs—from people with or at risk for skin diseases, as well as healthy volunteers. Researchers will use these samples to study the causes of skin conditions and explore potential treatments. Up to 700 particip…
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Scientists seek tissue samples to unlock HIV and cancer mysteries
Knowledge-focused Recruiting nowThis study collects blood, bone marrow, and tissue samples from people with HIV, KSHV, or certain cancers to help researchers learn more about these diseases. Participants must be 18 or older and may have HIV, KSHV, or related conditions. No treatment is given; the goal is to gat…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Scientists target Cancer's weak spot: redox imbalance
Knowledge-focused Recruiting nowThis study looks for new ways to kill T-cell leukemia and lymphoma cells by disrupting their internal balance of reactive oxygen species. Researchers will test drug combinations in lab-grown cells and in samples from 120 patients with resistant disease. The goal is to find treatm…
Sponsor: Istituto Oncologico Veneto IRCCS • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
HPV throat cancer study tracks hidden infections in women and partners
Knowledge-focused Recruiting nowThis study is checking how often women who have HPV-positive throat cancer, or whose partner has it, also have HPV infections in their genital or anal areas. Researchers will compare these rates to similar women without cancer. The goal is to learn more about how HPV spreads and …
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
Massive blood cancer registry aims to unlock secrets of adult ALL
Knowledge-focused Recruiting nowThis study is a large registry that will collect medical information and biological samples from up to 10,000 adults with acute lymphoblastic leukemia (ALL) and related blood cancers. The goal is to track how patients are diagnosed, treated, and how they fare over time. By gather…
Sponsor: Goethe University • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
What happens years after CAR-T therapy? a study aims to find out
Knowledge-focused Recruiting nowThis study follows people who previously received zamtocabtagene autoleucel, a CAR-T cell therapy for certain types of lymphoma. The goal is to monitor long-term health outcomes, including any new cancers, neurological issues, or autoimmune problems. By tracking participants over…
Sponsor: Miltenyi Biomedicine GmbH • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
Scientists collect samples to unlock secrets of lymphoid cancers
Knowledge-focused Recruiting nowThis study collects blood, urine, bone marrow, and tissue samples from over 1,200 adults with lymphoid cancers or precancerous conditions. The goal is to help researchers better understand cancer biology, which may lead to new methods for diagnosing or treating these diseases. No…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
NIH launches major study to unravel mysteries of long COVID recovery
Knowledge-focused Recruiting nowThis study follows 1,590 adults who have had COVID-19 to track their symptoms and recovery over three years. Participants complete phone interviews and online surveys every three months. The goal is to describe the range of recovery experiences and identify factors that lead to p…
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Dietary change explored as cancer support strategy
Knowledge-focused Recruiting nowThis early-stage study tests whether people with advanced solid tumors can safely follow a diet low in methionine, an amino acid found in many proteins. Researchers will measure how well participants stick to the diet, check for side effects, and track changes in blood methionine…
Phase: EARLY_PHASE1 • Sponsor: University of California, Irvine • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
Scientists launch Decade-Long watch on kaposi sarcoma
Knowledge-focused Recruiting nowThis study follows 150 adults with Kaposi sarcoma (KS) for up to 10 years to learn how the disease behaves, why it comes back, and how it affects the immune system and organs. Participants will have regular check-ups, scans, and biopsies, but no new treatments are being tested. T…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 01, 2026 00:00 UTC
-
What happens to the immune system after COVID-19? a major study aims to find out.
Knowledge-focused Recruiting nowThis study follows 800 adults who have recovered from COVID-19 to understand how their immune systems respond over the long term. By collecting blood samples and health data, researchers hope to uncover why some people develop lingering symptoms, known as Long COVID. The goal is …
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jul 25, 2026 00:00 UTC
-
Remote hearing tests could save cancer Patients' hearing
Knowledge-focused Recruiting nowThis study tests whether offering hearing tests close to home or remotely increases how many head and neck cancer patients get their hearing checked during treatment. Many patients on cisplatin chemotherapy or radiation near the ear can lose hearing, but not all complete recommen…
Phase: NA • Sponsor: Emory University • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
New 3D scanner could revolutionize how doctors measure kaposi sarcoma
Knowledge-focused Recruiting nowThis study will test a new 3D imaging device called SkinScan3D to see if it can measure Kaposi Sarcoma skin lesions more accurately and consistently than the current manual method. Researchers will compare the two methods in 300 adults with confirmed Kaposi Sarcoma who are starti…
Phase: NA • Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
Massive study aims to crack the code on Kids' medications
Knowledge-focused Recruiting nowThis study is collecting blood and other samples from 5,000 children and young adults (under 21) who are already taking certain medications as part of their regular care. The goal is to understand how these drugs move through and affect children's bodies, so doctors can prescribe…
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jul 17, 2026 00:00 UTC
-
New registry aims to unlock secrets of cancer in older adults
Knowledge-focused Recruiting nowThis research study creates a registry of older adults with cancer to collect information about their health, treatments, and outcomes. Participants complete a geriatric assessment and allow researchers to follow their medical records. The goal is to better understand how cancer …
Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Blood test may spot hidden sarcoma signals
Knowledge-focused Recruiting nowThis study investigates whether fragments of tumor DNA circulating in the blood can be used to detect and monitor soft tissue sarcoma. Researchers will collect blood and tumor tissue samples from 40 adults with high-risk sarcomas to see if this DNA can serve as a biomarker for ca…
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Hidden threat: hepatitis d prevalence under the microscope
Knowledge-focused Recruiting nowThis study aims to find out how often people with chronic hepatitis B also have hepatitis D, and which types of the virus are most common. Researchers will interview about 2,400 participants and take blood samples to look for links with vaccination history, lifestyle, and other f…
Sponsor: Tam Anh Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Long-Term heart risks after rare COVID complication in kids under scrutiny
Knowledge-focused Recruiting nowThis study looks at heart health in children five years after they had MIS-C, a rare but serious condition linked to COVID-19. Researchers will compare 90 children who had MIS-C with healthy children of the same age and sex. They will use heart imaging, blood vessel checks, exerc…
Sponsor: Medical University of Warsaw • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Scientists hunt for long COVID fingerprints in the brain and blood
Knowledge-focused Recruiting nowThis study looks for specific signs of long COVID in the brain and blood. Researchers will compare people with and without long COVID symptoms using brain scans and blood tests. The goal is to find objective markers that could help doctors diagnose long COVID more reliably.
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Blood cancer patients' journeys mapped over a decade
Knowledge-focused Recruiting nowThis study follows 500 adults in the Languedoc-Roussillon region of France who have or are suspected of having a blood cancer (hematologic malignancy). Researchers will collect medical records, blood samples, and quality-of-life questionnaires to track survival at 2, 5, and 10 ye…
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Austrian study seeks to eliminate hepatitis by linking patients to care
Knowledge-focused Recruiting nowThis study in South-East Austria looks at past lab results to find people with hepatitis B, C, or D who may not know they have it. Researchers will invite these individuals to a clinic to discuss treatment options. The goal is to connect them to care and track how many get cured,…
Sponsor: Vanessa Stadlbauer-Koellner, MD • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Lupus Patients' shingles vaccine response under the microscope
Knowledge-focused Recruiting nowThis study looks at how well the shingles vaccine (Shingrix) works in people with lupus compared to healthy people of the same age and sex. Researchers will measure immune cell responses after two doses and follow participants for up to 5 years. The goal is to understand if the v…
Sponsor: Seoul National University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Mapping the immune System's fight against certain cancers
Knowledge-focused Recruiting nowThis study looks at how T cells (a type of immune cell) respond to liver cancer and cancers linked to Epstein-Barr virus (EBV) and human papillomavirus (HPV). About 105 participants will give blood and tissue samples once. Researchers will analyze these samples to identify cancer…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Study tracks lingering COVID symptoms in 400 Pre-Surgery patients
Knowledge-focused Recruiting nowThis study looks at long-term health problems in 400 adults who had COVID-19 and are now preparing for surgery. Researchers will ask about ongoing symptoms like breathing issues, heart problems, and fatigue. No new treatments are given; the goal is to understand how past COVID-19…
Sponsor: Elazıg Fethi Sekin Sehir Hastanesi • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Crushed cancer pill study aims to help kids who Can't swallow tablets
Knowledge-focused Recruiting nowThis study looks at how the body processes venetoclax when the tablet is crushed and mixed into a liquid. It includes 30 children and young adults with blood cancers who already take venetoclax this way. The goal is to measure drug levels in the blood and spinal fluid to ensure t…
Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
New risk model may personalize Post-Chemo decisions for nasopharyngeal cancer
Knowledge-focused Recruiting nowThis observational study is testing whether a new tool called RAIRI can better identify which patients with nasopharyngeal cancer might benefit from additional therapy after standard chemoradiation. About 900 adults with non-metastatic disease will be followed to see if the RAIRI…
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Scientists seek tissue samples to unlock HIV-Cancer mysteries
Knowledge-focused Recruiting nowThis study collects blood and tissue samples from 200 adults with HIV and certain cancers (like Kaposi sarcoma, lymphoma, or anal cancer) to help researchers understand how HIV and cancer are connected. Participants donate samples, which are stored for future research. There is n…
Sponsor: AIDS Malignancy Consortium • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
New study hopes to predict hodgkin lymphoma outcomes better
Knowledge-focused Recruiting nowThis observational study is looking for better ways to predict how Hodgkin lymphoma will progress. Researchers will analyze genetic material from tumor samples and blood tests, along with PET scan images, from 755 patients. The goal is to identify markers that could help doctors …
Sponsor: Azienda USL Reggio Emilia - IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
New database aims to crack the code on three rare skin cancers
Knowledge-focused Recruiting nowThis study is building a large French database of patients with three rare skin cancers: Merkel cell carcinoma, advanced basal cell carcinoma, and cutaneous adnexal carcinomas. Researchers will track up to 9,000 participants to learn how these cancers behave, what factors affect …
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
New study aims to hear from NLPHL patients about their Real-Life experiences
Knowledge-focused Recruiting nowThis study collects information directly from people (ages 8 and older) with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) about their symptoms and quality of life. Participants will fill out surveys over time to help researchers understand how the disease and its treat…
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Massive T-Cell lymphoma database aims to unlock new insights
Knowledge-focused Recruiting nowThis study is creating a large database of information and tissue samples from 1,000 people with T-cell lymphoma. Researchers will use this data to learn more about the disease and how to improve patient outcomes. Participants provide medical information and optional blood and na…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Scientists hunt for clues in COVID Patients' blood and secretions
Knowledge-focused Recruiting nowThis study collects blood and nasal secretions from up to 2,000 people with COVID-19 to learn why some get very sick while others recover easily. Researchers will also track long-term symptoms like fatigue and brain fog. No treatments are tested—the goal is to gather data to guid…
Sponsor: Tulane University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Massive global registry aims to predict heart damage from cancer therapy
Knowledge-focused Recruiting nowThis study is a worldwide registry that follows 5,000 adults with breast cancer, blood cancers, or those on immune checkpoint inhibitors. Researchers collect medical records, lab results, and imaging to identify who is at risk for heart problems during or after cancer treatment. …
Sponsor: The Cleveland Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Can a simple test predict who will beat advanced nose cancer?
Knowledge-focused Recruiting nowThis study looks at 50 people with nasopharyngeal cancer that has come back or spread. Researchers will use advanced lab tests (multi-omics) to see if they can predict how well a combination of chemotherapy, radiation, and immunotherapy works. The goal is to find better ways to p…
Sponsor: Sun Yat-sen University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Mayo clinic launches study to uncover long COVID lung mysteries
Knowledge-focused Recruiting nowThis study aims to understand why some people continue to have symptoms like shortness of breath and fatigue long after a severe COVID-19 infection. Researchers will follow 67 adults for up to 12 months, using scans, blood tests, and other measures to look for clues in the lungs …
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Cancer immunotherapy may weaken bones, new study warns
Knowledge-focused Recruiting nowThis study looks at how immunotherapy drugs (anti-PD-1) affect bone strength in people being treated for cancer. Researchers will measure bone density and blood markers over a year in 25 patients. The goal is to understand if these treatments increase fracture risk, so doctors ca…
Phase: NA • Sponsor: Jessica Mezzanotte Sharpe • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
5,000 patients worldwide to help perfect cancer staging system
Knowledge-focused Recruiting nowThis international study aims to improve how doctors stage nasopharyngeal cancer by collecting data from 5,000 patients across multiple countries. Researchers will use this information to refine the TNM staging system and combine it with other factors like biomarkers. The goal is…
Sponsor: The University of Hong Kong-Shenzhen Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Mystery illness after COVID shot? new study seeks answers
Knowledge-focused Recruiting nowThis study looks at people who have long-lasting health problems after getting the COVID-19 vaccine, a condition called Post-Acute COVID-19 Vaccination Syndrome (PACVS). Researchers will track symptoms over eight months and test blood and blood vessel function to find biological …
Sponsor: University of Bern • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Rare ovarian cancer under the microscope: new study seeks answers
Knowledge-focused Recruiting nowThis study is collecting information from 30 patients with an extremely rare ovarian cancer called primary ovarian leiomyosarcoma. Researchers will look at past and new cases to find patterns in how the cancer is diagnosed and treated. The goal is to create better guidelines for …
Sponsor: Azienda USL Reggio Emilia - IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Scientists hunt for lymphoma genes in families with multiple cases
Knowledge-focused Recruiting nowThis study collects tumor samples and medical information from people with lymphoma or related blood cancers who have a family history of these diseases. Researchers want to find genetic changes that may increase the risk of developing lymphoma. Participants provide blood or tiss…
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Scientists probe cell energy in long COVID mystery
Knowledge-focused Recruiting nowThis study looks at how the body's cells use oxygen in people with long COVID compared to those fully recovered. Researchers will measure oxygen use in blood cells, skin, and muscle to see if there are differences. The goal is to better understand long COVID and test if these mea…
Sponsor: Universitair Ziekenhuis Brussel • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Body clock may hold key to long COVID recovery
Knowledge-focused Recruiting nowThis study looks at how different sleep-wake patterns (called circadian rhythms) affect breathing strength, physical activity, and eating habits in people with Post-COVID syndrome. Researchers will study 50 adults aged 18-65 who have been diagnosed with long COVID. The goal is to…
Sponsor: Hacettepe University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
New study tracks hidden organ damage after COVID-19
Knowledge-focused Recruiting nowThis study follows 650 adults in Quebec to learn about the short- and long-term health problems caused by COVID-19, including damage to the heart, lungs, kidneys, and other organs. Participants include people who had mild, moderate, or severe COVID-19, as well as those who never …
Sponsor: Emilia Falcone, MD • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Shingrix vaccine under the microscope: can it shield patients on Immune-Weakening drugs?
Knowledge-focused Recruiting nowThis study looks at how the Shingrix vaccine (for shingles) works in people with psoriasis or myelofibrosis who are taking drugs that weaken their immune system. Researchers will compare their immune response to that of similar patients not on these drugs. The goal is to understa…
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Scientists probe blood vessel role in skin disorders
Knowledge-focused Recruiting nowThis study looks at how abnormal blood vessel growth (angiogenesis) contributes to various skin diseases like rosacea, psoriasis, and certain tumors. Researchers will collect skin samples from 85 volunteers aged 16 and older to analyze markers of angiogenesis. The goal is to bett…
Sponsor: University of California, Irvine • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
New embryo DNA test aims to cut miscarriages in PCOS patients
Knowledge-focused Recruiting nowThis study compares two ways to screen embryos in women with polycystic ovary syndrome (PCOS) undergoing IVF. One method looks at DNA methylation patterns (PIMS), while the other checks for chromosome issues (PGT-A). The goal is to see if PIMS can lower the rate of early pregnanc…
Phase: NA • Sponsor: First Affiliated Hospital, Sun Yat-Sen University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Massive european study launches to unlock secrets of rare head and neck cancers
Knowledge-focused Recruiting nowThis large observational registry aims to collect data from over 13,000 adults across Europe with rare head and neck cancers, including cancers of the nasopharynx, nasal cavity, salivary glands, and middle ear. Researchers will track patient outcomes like survival, treatment resp…
Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:03 UTC
-
Veterans' brain fog after COVID: new study seeks answers
Knowledge-focused Recruiting nowThis study looks at why some veterans experience ongoing brain fog and other mental health issues after COVID-19. Researchers will track 200 veterans over time, using memory tests and blood samples to find clues. The goal is to better understand these symptoms and identify target…
Sponsor: VA Office of Research and Development • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
New tool aims to predict cancer treatment toxicity in older patients
Knowledge-focused Recruiting nowThis study is testing a new tool designed to predict side effects from cancer treatment in elderly patients (70+) with advanced head and neck cancer. The goal is to see if the tool can help doctors choose safer treatments. Only 3 participants are being enrolled, making this a ver…
Sponsor: European Institute of Oncology • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
New 3D camera could revolutionize how we track kaposi sarcoma
Knowledge-focused Recruiting nowThis study tests a new 3D imaging device called SkinScan3D to see if it can take better pictures of Kaposi sarcoma (KS) skin lesions than standard 2D photos. KS lesions can change in height when they respond to treatment, which 2D photos miss. The study will enroll 30 adults with…
Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Gum disease and hepatitis: a hidden connection revealed?
Knowledge-focused Recruiting nowThis study looks at the link between gum (periodontal) disease and hepatitis B+D infection, and whether the drug bulevirtide changes that relationship. Researchers will measure inflammation markers in saliva and gum fluid from 25 adults: those with hepatitis B+D on bulevirtide, t…
Sponsor: Research Center of Periodontal-Systemic Interactions • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Long COVID secrets revealed? 4-Year study tracks 400 patients
Knowledge-focused Recruiting nowThis study follows 400 adults with long COVID for four years to understand how the condition changes over time. Researchers will look at blood markers, blood vessel health, and fatigue levels. The goal is to find better ways to diagnose and manage long COVID in the future.
Sponsor: Instituto de Investigación Biomédica de Salamanca • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Can a simple blood test predict cancer return? new study investigates
Knowledge-focused Recruiting nowThis study looks at whether a blood test can detect HPV DNA in people with HPV-related anal or cervical cancer who are receiving radiation therapy. Researchers will collect blood samples before, during, and after treatment to see if the virus's genetic material shows up and if it…
Sponsor: University of Chicago • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Chemo brain hits blood cancer patients too – new study investigates
Knowledge-focused Recruiting nowThis study looks at memory, concentration, and language problems caused by chemotherapy in people with blood cancers like leukemia and lymphoma. Researchers will compare 120 patients to their healthy relatives using tests and questionnaires before and after treatment. The goal is…
Sponsor: University Hospital, Angers • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
New app aims to empower hepatitis delta patients in their own care
Knowledge-focused Recruiting nowThis study is testing a mobile app called ePro-Diary HDV for people with hepatitis Delta, a rare but serious liver disease. The app helps patients track their health, communicate with doctors, and remember appointments. Researchers want to see if using the app helps patients atte…
Sponsor: FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Gut bacteria clues may unlock long COVID mysteries
Knowledge-focused Recruiting nowThis study aims to understand how changes in gut bacteria (dysbiosis) affect the immune system and gut health in people with long COVID. Researchers will collect stool and blood samples from 400 adults—half with long COVID symptoms and half without. The goal is to find links betw…
Sponsor: University of Chicago • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
Leukemia treatment may erase vaccine protection—study tests if re-vaccination works
Knowledge-focused Recruiting nowThis study looks at whether children and young adults (up to age 21) treated for B-cell acute lymphoblastic leukemia with the immunotherapy drug blinatumomab still have protection from routine childhood vaccines. Researchers will measure antibody levels for diseases like tetanus,…
Sponsor: Arkansas Children's Hospital Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
800-Patient study aims to tailor sarcoma treatment
Knowledge-focused Recruiting nowThis study is collecting tissue samples and medical data from 800 high-risk sarcoma patients to develop personalized treatment approaches. Researchers will analyze genetic and protein profiles to better predict which patients benefit from chemotherapy before surgery. The goal is …
Sponsor: Royal Marsden NHS Foundation Trust • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
Gut check: new study probes how hepatitis drug changes your microbiome
Knowledge-focused Recruiting nowThis study looks at how the drug bulevirtide changes gut bacteria and bile acids in people with hepatitis delta (a serious liver infection). Researchers will follow 20 patients for 48 weeks, collecting stool and blood samples to see how these changes relate to liver health. The g…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
New registry aims to unravel mysteries of long COVID
Knowledge-focused Recruiting nowThis observational study will enroll 200 people in Navarre who have had COVID-19 and still have symptoms lasting more than 3 months. Researchers will collect information on demographics, health history, and ongoing symptoms to better understand long COVID. The goal is to describe…
Sponsor: Fundacion Miguel Servet • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
800 patients to help scientists grow liver tumors in the lab
Knowledge-focused Recruiting nowThis study collects blood and tissue samples from 800 people with chronic liver disease or liver cancer. Researchers will use these samples to create lab models, such as cell clusters and mouse tumors, to study these diseases and test new treatments. The goal is to improve unders…
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
New study scans brains to uncover why COVID-19 triggers depression
Knowledge-focused Recruiting nowThis study uses PET and MRI scans to look at brain changes in people who developed depression within three months after a mild or moderate COVID-19 infection. Researchers will compare brain scans of 90 participants to see if key brain chemicals are altered. The goal is to better …
Sponsor: Centre for Addiction and Mental Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
Tiny study probes Electroacupuncture's immune effects in shingles
Knowledge-focused Recruiting nowThis study looks at how electroacupuncture might affect immune cells in people with shingles (herpes zoster). Researchers will compare standard medication alone versus medication plus electroacupuncture in 8 women aged 50-70. The goal is to see if electroacupuncture changes immun…
Phase: NA • Sponsor: First People's Hospital of Hangzhou • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Scientists hunt for hidden genes behind Family-Linked blood cancers
Knowledge-focused Recruiting nowThis study aims to find the genetic causes of certain blood cancers like lymphoma, leukemia, and multiple myeloma by studying families where more than one person has the disease. Researchers will collect DNA and blood samples from up to 500 participants, including patients and th…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Veterans study: does poor sleep worsen long COVID brain fog?
Knowledge-focused Recruiting nowThis study looks at how sleep issues and sleep apnea might affect thinking, memory, and daily life in people who had COVID-19. Researchers will follow 200 veterans for up to a year, testing their brain function, sleep quality, and exercise ability. The goal is to find out if trea…
Sponsor: VA Office of Research and Development • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Long-COVID mystery: new study aims to decode patient subtypes
Knowledge-focused Recruiting nowThis study looks at 150 adults with long-COVID to group them by their symptoms and link those groups to lab results. The goal is to find patterns that could help doctors predict outcomes and discover new treatments. Participants will have their health data and blood samples analy…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Housebound no more: new study brings doctors to the bedside of ME/CFS patients
Knowledge-focused Recruiting nowThis study focuses on people with ME/CFS or Long COVID who are too sick to leave home. Researchers will provide monthly in-home medical visits and create personalized care plans. The goal is to see if this approach improves patients' health and eases the burden on their caregiver…
Phase: NA • Sponsor: Hannover Medical School • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Blood test may outsmart PET scans in childhood cancer
Knowledge-focused Recruiting nowThis study is testing whether a simple blood test (called a liquid biopsy) can better predict relapse in children and young adults with classical Hodgkin lymphoma. Researchers will track 400 patients under 25 to see if tumor DNA in the blood can catch early signs of relapse or tr…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
Scientists track immune cells in hepatitis d patients on new drug
Knowledge-focused Recruiting nowThis study looks at how the immune system fights hepatitis D in people who also have hepatitis B. Researchers will measure special immune cells (T cells) in 192 adults before and after 12 months of treatment with the drug bulevirtide. The goal is to see if these immune responses …
Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
AI takes on mysterious uterine tumors: a new hope for accurate diagnosis
Knowledge-focused Recruiting nowThis study is testing whether artificial intelligence can help doctors better classify and predict the behavior of rare smooth muscle tumors of the uterus, including those that are hard to diagnose (called STUMP). Researchers will train AI models on digital images of tumor tissue…
Sponsor: Institut Bergonié • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
New rapid test could transform hepatitis b and d management
Knowledge-focused Recruiting nowThis observational study aims to develop a rapid T-cell test to help manage patients with chronic hepatitis B (HBV) and hepatitis B/D (HBV/HDV) co-infection. Researchers will analyze immune responses in 300 adult patients to understand how T-cells react to the viruses. The goal i…
Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC